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Abstract 
Dendritic cells (DCs) have a unique capacity to induce immune responses against 
tumor cells. They can phagocyte tumor antigens, maturate and present them to T cells, 
triggering antigen-specific immune responses that may lead to the elimination of tumor 
cells. Since they induce long-lasting immunological memory, DCs become an attractive 
strategy as cellular targets for vaccines in the treatment and/or prevention of cancer. 
However, the therapeutic results obtained in clinical trials with DCs are scarce and only 
few patients effectively respond to the DC vaccines. Our group has shown that sialic acid 
containing glycans play an important functional role in ex vivo generated DC. Here we 
aimed to establish an in vitro model to assess specific antitumor responses. To achieve this, 
an enzymatic treatment of monocyte-derived DCs (moDCs) was performed using sialidase 
to cleave surface sialic acids. The maturation profile of the moDCs was characterized by 
flow cytometry and cytokine expression. The results show that sialidase treatment can 
upregulate co-stimulatory molecules on surface of moDCs stimulated with Toll like 
receptor (TLR) agonists. To understand whether sialidase treatment affected the TLR 
signaling, we have used HEK cells stably transfected with TLRs 2, 4 and 7/8. The data 
showed that desialylation of moDCs does not affect the signaling via these receptors. To 
investigate the functional impact of sialidase treatment in the capacity of moDCs to present 
antigen and to activate antigen specific T cells, sialidase treated and untreated moDCs were 
co-cultured with CD8+ T cell clones specific for peptides derived from the gp100 tumor 
antigen. Our results show that desialylated HLA02:01+ DCs are superior in cross-
presentation of the peptide to gp100280–288 specific CD8
+ T cells. In addition, sialidase 
treatment also increased the DC capacity to induce CD4+ T cells proliferation. Together, 
these data indicate that moDCs with altered cell surface sialic acids, through a sialidase 
treatment, have a better immunostimulatory potential which could improve anti-tumor 
immune responses. 
Key words: moDCs, glycans, sialidase, desialylation, therapy, gp100 peptide, TLR  
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Resumo 
As células dendríticas (DCs) têm a capacidade única de induzir respostas 
imunitárias contra as células tumorais, fagocitando antigénios tumorais e apresentando-os 
às células T, provocando respostas imunitárias específicas que conduzem à eliminação de 
células de tumorais. Por induzirem memória imunológica de longa duração, as DCs são 
uma estratégia atrativa para o tratamento e/ou prevenção do cancro. No entanto, os 
resultados terapêuticos obtidos em ensaios clínicos com DCs são escassos e pouco 
eficientes. O nosso grupo demonstrou que ácidos siálicos que contêm glicanos 
desempenham um papel funcional importante em DCs geradas ex vivo. Com o objetivo de 
estabelecer um modelo in vitro para avaliar a resposta anti-tumoral específica realizou-se 
um tratamento enzimático a DCs derivadas de monócitos (moDCs) com sialidase, enzima 
que cliva ácidos siálicos na superfície celular. O perfil de maturação de moDCs foi 
caracterizado por citometria de fluxo e expressão de citocinas. Os resultados mostram que a 
sialidase pode regular positivamente a expressão de moléculas co-estimuladoras na 
superfície de moDCs estimuladas com agonistas de Toll like receptors (TLRs). Para 
percebermos se o tratamento com sialidase afeta a sinalização dos TLRs foram usadas 
células HEK transfectadas de forma estável com TLRs 2, 4 and 7/8. Os dados mostraram 
que a desialilação não afeta a sinalização através estes recetores. Para investigar o impacto 
funcional da sialidase na capacidade de moDCs em apresentar um antigénio e ativar células 
T, moDCs foram tratadas, ou não, com sialidase e cultivadas com clones de células T CD8+ 
específicas para os péptidos derivados do antigénio tumoral gp100. Os resultados mostram 
que DCs HLA*02:01+ desialiladas exibem maior cross-presentation do péptido gp100280-288 
às células T CD8+ específicas. Além disso o tratamento com sialidase também aumenta a 
capacidade de DCs de induzir a proliferação de células T CD4+. Em conjunto, os resultados 
indicam que moDCs com menos ácidos siálicos na superfície, têm melhor potencial imuno-
estimulador, com maior capacidade de induzir respostas imunes anti-tumorais.  
Palavras-chave: moDCs, glicanos, sialidase, desialylation, terapia, peptídeo gp100 
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For a good functioning of the human body a balance must exist between 
proliferation and cell death (Baehrecke, 2002). However, due to external or internal 
conditions, mutations occur during the generation of new cells which could lead to 
disruption of this homeostasis since these cell lose the ability to respond to stimulus 
(Kumar, V., Abbas A. K., Fausto, N. & Mitchell, 2007).  
Transformation of normal cells into cancer cells is associated with phenotypic 
changes that affect the behavior of cells and consequently other biological processes. 
Hanahan and Weinberg (Hanahan e Weinberg, 2011), described the main aspects that 
characterize cancer: evasion of apoptosis, inadequate signs to inhibit cell growth, the ability 
to proliferate indefinitely, acquiring modifications that allow invasion of other tissues and 
tumor vascularization. All of them allow tumor cell survival and uncontrolled cell 
proliferation that leads to invasion of other tissues and subsequent metastasis (Bogenrieder 
e Herlyn, 2003; Goldsby, R.A., Kindt, T. J., Osborne, B., Kuby, 2003; Hanahan e 
Weinberg, 2011; Kumar, V., Abbas A. K., Fausto, N. & Mitchell, 2007), the main cause of 
death in people with cancer (EL, 1997). 
These characteristics (Hanahan e Weinberg, 2011) distinguish cancer cells from 
normal cells, potentially allowing the tumors to be recognized as "foreign" by the immune 
system (Chen, Irving e Hodi, 2012; Gros et al., 2014; Mellman, Coukos e Dranoff, 2011; 
Rooij, van et al., 2013). However, tumors are rarely rejected spontaneously, reflecting their 
ability to maintain an immunosuppressive microenvironment (Chen e Mellman, 2013). 
Thus, it is necessary around this to capture tumor antigens by antigen presenting cells 
(APCs) (such as dendritic cells) so that these tumor epitopes are processed and presented to 
immune effector cells (lymphocytes) (Arosa, A. F., Cardoso, E.M., 2011).  
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In 2012, worldwide (World cancer research fund international) 14.1 million new 
cancer cases were diagnosed of which 8.2 million died. It is estimated that in 2035 the 
number of persons with cancer will increase dramatically to 24 million. 
Conventional therapies such as surgical resection and a combination of 
chemotherapy and radiotherapy are approaches that are often accompanied by unintended 
collateral damage and with high toxicity to healthy tissues and have not been sufficiently 
effective in the fight against cancer. It is of great importance to develop a therapy that uses 
the patient's own immune system and, in that way, ensures the safety of patients while 
being effective in eliminating the tumor. 
 
1.2) Immune system  
The immune system has the ability to respond to different external aggressions, in 
particular antigenic natures that are foreign to the body, whether a microorganism or 
macromolecule, and various internal injuries, or modified tumor cells. Thus, you can define 
immunity as a set of defense mechanisms that our body has to protect itself from attacks, to 
maintain the immune homeostasis. The immune system under normal conditions doesn´t 
present any kind of response to host cells, a situation that it is known as immunological 
tolerance (Arosa, A. F., Cardoso, E.M., 2011).  
 
1.2.1) Innate and adaptive immunity 
The reaction of the immune system can be divided into two types of interconnected 
pathways: innate immunity and adaptive immunity.  
Innate immunity is the first line of the body's defense and it is mainly mediated by 
neutrophils, macrophages, natural killer cells (NK) and dendritic cells (DCs), commonly 
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known as phagocytic cells, which phagocytose the foreign body and destroy it (Akira, 
2011). 
This is an immediate response with a broad spectrum specificity, recognizing only 
molecular patterns stored in microorganisms or PAMPs (Pathogen-associated molecular 
patterns) through specific receptors on phagocytic cells (macrophages and DCs). These 
receptors are called pattern recognition receptors (PRRs) and include the Toll-like receptors 
(TLRs) and C-type lectin receptors (CLRs), such as the mannose receptor. TLRs are able to 
recognize a wide variety of PAMPs. This recognition results in the activation of phagocytic 
cells that can lead to the internalization of the microorganism, as well as the release of 
cytokines and inflammatory mediators, triggering an inflammatory process (Arosa, A. F., 
Cardoso, E.M., 2011). In contrast to adaptive immunity, each time the body is exposed to 
the pathogen, the immune response is always the same, since there is no memory on 
previous exposures.  
Cytokines released by cells from inflamed tissues, such as interleukin-1 (IL-1) and 
interleukin-6 (IL-6) are important in activation of immune response and cell interaction. Then, 
mononuclear cells and lymphocytes, that in the meantime, are attracted to the inflammatory 
focus, are activated and start releasing their own cytokines (IL-1, IL-2, IL-4, TNF-α, IFN- γ, 
etc.) enhancing and promoting the migration and activation of certain cells more directly 
involved in the immune response (Akira, 2011; Arosa, A. F., Cardoso, E.M., 2011). 
Adaptive immunity is the more delayed response of the immune system and requires 
the clonal proliferation of effector cells (T and B lymphocytes), which have to capacity to form 
memory cells and is therefore more effective (Seeley, 2003). This response requires activation 
of T and B lymphocytes, which is mainly performed by professional APCs, such as DCs, that 
after the capture of antigen, processes it and migrate to the lymph nodes where it is presented to 
T cells (fig.1). 
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Figure 1 - Immune System: Innate immunity and adaptive immunity. 









While the B cell receptor recognizes the antigen in its native form (not processed), 
the T cell receptor only recognizes the antigen in a fragmented form (for example peptides) 
presented in the context of MHC (Major Histocompatibility Complex) molecules. This 
recognition results in activation and differentiation of B lymphocytes, which will produce 
antibodies specific to the antigen, and the activation and differentiation of T lymphocytes, 
which lead to the formation of effector cells and regulatory cells of the immune response 
(Arosa, A. F., Cardoso, E.M., 2011). 
 
1.2.2) T lymphocytes 
T cells are a lymphocyte lineage originated from bone marrow hematopoietic 
precursors which complete their maturation in the thymus. These cells are roughly divided 
into four groups: helper T lymphocytes (Th), cytotoxic T cells (CTL), regulatory T cells 
(Treg) and natural killer T lymphocytes (NKT) (Arosa, A. F., Cardoso, E.M., 2011). 
The Th cells express CD4 and their function is to produce cytokines that, in turn, 
will help in the activation of other immune cells. The formation of the tri-molecular 
complex TCR/peptide /MHC allows the presentation of the peptide by APCs to Th cells, 
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which is restricted by antigen presentation in MHC class II molecules. After activation, the 
Th lymphocytes begin a differentiation process, and can develop into four types of 
lymphocytes: Th1, Th2 and Th17 (Goldsby, R.A., Kindt, T. J., Osborne, B., Kuby, J, 2007). 
The Th1 lymphocytes are characterized by production of IL-2, IFN-γ and TNF-β. 
The function of IL-2 is to regulate the growth of Th1 cells as well as CD8+ T lymphocytes.  
The Th2 lymphocytes are characterized by production of IL-4, IL-5, IL-9, IL-10 and 
IL-13 (anti-)inflammatory cytokines responsible for regulating the humoral response 
against extracellular pathogens and allergens (Goldsby, R.A., Kindt, T. J., Osborne, B., 
Kuby, J, 2007). 
The CTL express CD8, and their function is to eliminate other cells, particularly 
when they have become a tumor or are infected. The CTL response is restricted by antigen 
presentation in MHC class I molecules and is characterized by production of the cytokines 
IFN-γ and TNF-α and lytic enzymes (perforin and granzymes), responsible for the 
elimination of target cells (Arosa, A. F., Cardoso, E.M., 2011). 
The Treg derived from a separate “lineage” of lymphocytes (not Th) and function as 
controllers of the immune response and play an important role in the maintenance of 
immunological tolerance to innocuous antigens in the periphery and in the prevention of 
autoimmunity, allergies and, in general, are responsible for the suppression of immune 
responses (Lehtimäki e Lahesmaa, 2013). 
The NKT cells contain mixed features of T and NK lymphocytes and are 
determinants of infectious and autoimmune diseases. NKT cells express a particular type of 
TCR that recognizes glycolipid antigens in the context of non-classical MHC CD1d and 
once activated are cytotoxic and produce cytokines such as IL-4 and IFN-γ (Wu e Kaer, 
Van, 2009). Although NKT can directly eliminate tumor cells, it is believed that their 
effectiveness arises from the effect on NK cells, CD8+ T cells and DCs, leading,  
particularly in DCs, to their activation/maturation via IFN-γ production (Terabe e 
Berzofsky, 2008). 
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T cell activation begins with the recognition by the TCR/CD3 of antigenic peptides 
exposed on the surface of APCs in association with MHC molecules. The signal from the 
TCR /CD3-MHC-peptide interaction is the primary activation signal ("signal 1"), which 
confers specificity to the adaptive response. However, this signal in itself is not effective to 
induce strong activation that causes the naive CD4+ T and naive CD8+ T lymphocytes to 
enter the cell cycle and to proliferate, making it necessary to receive accessory signals. 
These accessories signals are transmitted by the CD28 receptor, considered "Signal 2", 
which will lead to the formation of CD4+ T and CD8+ T lymphocytes with different 
phenotypic and functional characteristics than the initial naive T lymphocyte (Arosa, A. F., 
Cardoso, E.M., 2011). 
 
1.3) Dendritic cells 
 
1.3.1) Origin, differentiation and classification 
DCs were identified for the first time by Paul Langerhans in 1968, who mistakenly 
thought they were part of the nervous system (Langerhans cells, LCs) (Goldsby, R.A., 
Kindt, T. J., Osborne, B., Kuby, J, 2007). This concept held until the mid-twentieth century. 
In 1973 Ralph Steinman and Zanvil Cohn observed a cell population in the spleen with a 
dendritic shape and demonstrated that this was a new class of cells with 
immunomodulatory functions in the immune system (Paczesny S., 2003). 
Currently, it is known that DCs originate from CD34+ hematopoietic stem cells 
(HSCs) from the bone marrow. In physiological stress conditions, monocytes can 
differentiate into immature DCs in the presence of the stimulating factor, granulocyte 
macrophage colony (GM-CSF) and from a variety of other cytokines (Mogensen, 2009).  
The enormous heterogeneity presented by DCs makes for its rather complex 
classification, however, generally it can be classified as plasmacytoid DCs (pDCs), or 
myeloid DCs (mDCs) depending on specific characteristics, such as the expression of 
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surface markers, location in the body. Both mDCs and pDCs perform specific functions and 
specific inflammatory stimulus that induce differentiation (Arosa, A. F., Cardoso, E.M., 
2011). 
The pDCs can be derived from myeloid precursor and are in the blood and 
lymphoid organs (Sathe et al., 2013). These cells are characterized by their extraordinary 
ability to produce interferon type 1 (IFN-α / β) following viral infection or after interaction 
with TLRs 7 and 9 agonists. From a functional standpoint, pDCs have an enormous 
plasticity and can induce Th responses (Th1 and Th2), or tolerance via induction of Treg 
cells. Moreover, they are still capable to perform antigen cross-presentation via MHC class 
I, due to their special endosomal compartments (Arosa, A. F., Cardoso, E.M., 2011; 
McKenna, Beignon e Bhardwaj, 2005). 
Likewise, mDCs are from the myeloid lineage and can be found in tissues 
(Langerhans cells and interstitial DCs) and in peripheral blood (inflammatory DCs) 
(Brussel I.V., Berneman Z.N., 2012; Paczesny S., 2003; Zhang, C. e Engleman, 2006). 
Inflammatory DC are involved in recognition of bacterial structures and production of  pro-
inflammatory cytokines, including tumor necrosis factor α (TNF-α), IL-6 and IL-12p70 to 
activate Th1 / Th17 cells, and thus recruiting CTLs (Arosa, A. F., Cardoso, E.M., 2011; 
Zhang, C. e Engleman, 2006).  
It has been further shown that pDCs can enhance the immune response through 
cross-talk with mDCs through IFN-γ production and CD40L expression, enabling the 
production of IL-12p70 by the mDC ( Boudreau J. E., Bonehill A., Thielemans K., 2011). 
1.3.2) Antigen recognition and uptake  
Acting as sentries in peripheral tissues, the main function of DCs is antigen 
presentation to T lymphocytes. These cells are considered to be professional APCs and are 
able to endocytose and process any type of antigen and to present it in the context of MHC 
molecules. For this reason the DCs are better equipped compared to macrophages and B 
cells. Another feature that distinguish them as professional APCs, is the so-called 
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maturation process in which immature DC with large endocytic capacity and low 
expression of MHC-II molecules, differentiate into mature DC characterized by a low 
endocytosis capacity and a high expression of MHC-II molecules. The immature DCs, 
lying in organs and peripheral tissues, have a great ability to endocytose and process 
endogenous and exogenous antigens while mature DCs are specialized in the activation of 
T lymphocytes in secondary lymphoid organs. 
Generally, endogenous antigens presented by DCs in the context of MHC-I activate 
CD8+ T lymphocytes, while exogenous antigens are presented by DCs in the context of 
MHC II activate CD4+ T lymphocytes. DCs also have the unique ability to present 
exogenous antigens in vivo to CD8+ T lymphocytes via MHC-I, in a process called cross-
presentation (Arosa, A. F., Cardoso, E.M., 2011; J. E. Boudreau, A. Bonehill, K. 
Thielemans, 2011). 
1.3.2.1) Receptors in the antigen recognition and uptake 
The designated PAMPs, which are highly conserved structures including microbial 
lipids, polysaccharides, nucleic acids and viral RNA, are recognized by immature DCs 
through PRRs. These receptors are highly diverse, which includes TLRs, nucleotide-
binding oligomerization domain (NOD-like) receptors and CLRs (Kanazawa, 2007; 
Mogensen, 2009). 
After antigen recognition, their internalization is mediated by a large number of 
endocytic and phagocytic receptors including CLRs and integrins. 
The TLRs are transmembrane proteins which are present in DCs, macrophages, 
fibroblasts and epithelial cells. They are involved in recognition of antigens and subsequent 
activation of cell signaling pathways. mDCs express TLR 1–8, which when stimulated, 
upregulate activation markers (CD80, CD86, MHC class I and II), produce pro-
inflammatory cytokines (TNF-α, IL-1, IL-6, IL-12), chemokines, adhesion molecules 
(ICAM-1) and prime antigen-specific CD4+ and CD8+ T cells (Gnjatic, Sawhney and 
Bhardwaj, 2010 ). Activation of TLRs by exogenous or endogenous ligands induces DC 
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maturation and activation, thereby determining the onset of immune responses (Arosa, A. 
F., Cardoso, E.M., 2011).  
 
 
Table 1 - Synthetic ligands of Toll-like receptors and respective PAMPs.  
                Adapted from Gnjatic et al.,(Gnjatic, Sawhney and Bhardwaj, 2010). 
 
Receptor Pathogen Associated ligands (PAMPs) Synthetic ligands 
TLR ½ Triacylated lipopeptides (Bacteria and Mycobacteria)* Pam3CysK4 
TLR 4 Lipopolysaccharide (LPS) (Gram-negative bacteria); LPS 
TLR 7 Viral ssRNA (Influenza, VSV, HIV, HCV) Guanosine analogs; imidazoquinolines 
(e.g.R848, Resiquimod®); Loxoribine. 
TLR 8 ssRNA from RNA virus Imidazoquinolines (e.g.R848, 
Resiquimod®); Loxoribine. 
 
NOD-like receptors are located in cytoplasm of the DC and are capable of binding 
to bacterial peptidoglycans (Kanazawa, 2007). 
The CLRs recognize and internalize antigen to the intracellular compartments of 
DCs, which subsequently leads to processing and presentation of the antigens via MHC-I 
and MHC-II. The mannose receptor/CD206, langerin/CD207, present on Langerhans cells, 
DC-SIGN/CD209 and DEC205/CD205 are examples of CLRs (Kanazawa, 2007). Recent 
studies have demonstrated that CLRs are involved in antigen internalization by DCs, in 
activation of intracellular signaling pathways including nuclear transcription factor kappa B 
(NF-kB), and also in inducing cytokine expression which determines the polarization of Th 
lymphocytes (Arosa, A. F., Cardoso, E.M., 2011). 
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1.3.3) Antigen processing 
Before antigen detection, DCs are in an immature stage. After recognition, DCs 
phagocytose the antigen and then enter an activation process, maturation, and migrate to the 
lymph nodes where a T cell immune response specific for the antigen is initiated. During 
the process of maturation and migration, DCs process the antigen into smaller fragments 
that may be presented to T lymphocytes (Hamdy et al., 2011).  
DCs process endogenous and exogenous antigens, presenting them to T 
lymphocytes in the form of antigenic peptides bound to MHC molecules (Hamdy et al., 
2011). This processing is different based on the origin and the molecular nature of antigen, 
whereby presentation occurs via three mechanisms: i) via MHC class I or cytosolic 
(endogenous); ii) via MHC class II or endocytic (exogenous); iii) presentation of lipid 
antigens coupled to CD1 molecules (Goldsby, R.A., Kindt, T. J., Osborne, B., Kuby, J, 
2007).   
Extracellular antigens are captured by endocytosis, phagocytosis and pinocytosis, 
which enter the endocytic pathway, forming endosomes that subsequently undergo 
maturation and fusion with lysosomes. In lysosomes hydrolytic enzymes cleave the antigen 
into smaller molecules, peptides, which are then coupled to MHC-II molecules. The MHC-
peptide complex is transported to the cell surface during the process of dendritic cell 
maturation for antigen presentation to CD4+ T naive lymphocytes (Goldsby, R.A., Kindt, T. 
J., Osborne, B., Kuby, J, 2007). 
Through the cytosolic pathway, intracellular antigens (which may be self-proteins 
or of pathogenic or viral origin) are ubiquitinated and degraded by proteasomes into 
peptides. Through the transporter associated with antigen processing (TAP) the peptides are 
directed to the endoplasmic reticulum where they bind to MHC-I molecules. The MHC I-
peptide complex is then transported to the cell surface where antigen presentation to naive 
CD8+ T cells can occur (Goldsby, R.A., Kindt, T. J., Osborne, B., Kuby, J, 2007). 
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1.3.4) DC maturation 
In peripheral tissues DCs are usually in an immature state and practically devoid of 
immunostimulatory activity. However, after a stimulus (danger signal - antigen) they 
acquire different morphological, phenotypic and functional properties. In an immature 
state, DCs have a low ability to stimulate immune responses and a high power to capture 
antigens. When the maturation process starts, DCs lose their phagocytic receptors and 
increase their migration from peripheral tissues to secondary lymphoid organs where they 
present antigen to naive lymphocytes, culminating in the acquisition of immunostimulatory 
potential (maturation). antigen processing is regulated in a coordinated manner through 
maturation of the DC, which causes a decrease in  pH of the endosomes, whereby 
processing is facilitated, enabling the transport of the MHC-peptide complex to the cell 
surface (Arosa, A. F., Cardoso, E.M., 2011). 
Indeed, mature DCs express high levels of costimulatory molecules, as well as 
MHC molecules and synthesize high levels of IL-12 which enhances the ability to induce 
innate (NK cells) and adaptive (T and B cells) responses (Brussel I.V., Berneman Z.N., 
2012). This process is continuous and highly regulated by signal transduction pathways that 
can be triggered directly through recognition of pathogens via PRRs or indirectly by 
exposure to other inflammatory mediators produced by immune cells, which results in 
increased membrane expression of costimulatory molecules (Brussel I.V., Berneman Z.N., 
2012; Neves, 2010). The increased expression of MHC class I and class II and 
costimulatory molecules CD40, CD83, CD80 and CD86 during maturation is crucial in 
order to establish the immunological synapse and consequent stimulation of lymphocytes 
(Arosa, A. F., Cardoso, E.M., 2011). 
The stimuli that induce maturation include products of microorganisms that bind to 
pattern recognition receptors, immune complexes that act on Fc receptors, inflammatory 
molecules released from the host cells, particularly CD40L, TNF-α, IL-1β, IL-6 e IFN-γ, 
and molecules released from damaged tissues such as uric acid (Arosa, A. F., Cardoso, 
E.M., 2011; Wu, Wang e Zhang, 2004). 
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1.3.5) Antigen presentation by DCs to T cells 
In the lymph nodes, DCs present antigen to CD4+ and CD8+ T cells via MHC II and 
MHC-I, respectively. This interaction results in the activation of CD8+ T lymphocytes and 
the differentiation of CD4+ T lymphocytes in their different effector and/or regulatory cells. 
For this it is necessary that the antigenic recognition via MHC and interaction between 
costimulatory molecules on DCs and their respective ligands on T cells occurs (J. E. 
Boudreau, A. Bonehill, K. Thielemans, 2011).  
In addition, DCs also have a unique ability to present exogenous antigens via MHC-
I molecules. This function is referred to as cross-presentation of antigens. Exogenous 
antigens can be derived from apoptotic tumor cells or apoptotic infected cells (viral or 
bacterial). These antigens are degraded by the proteasome and coupled to MHC-I 
molecules for presentation to naive CD8+ T lymphocytes. This process ensures that DCs are 
able to create a cytotoxic immune response against tumor or infected cells. However, the 
cross-presentation process can yield, by the CD8+ T cells both effective immunity (cross-
priming) and tolerance (cross-tolerance). Nevertheless, this mechanism has been crucial in 
the formulation of anti-tumor vaccines (Arosa, A. F., Cardoso, E.M., 2011; Goldsby, R.A., 
Kindt, T. J., Osborne, B., Kuby, J, 2007; Hamdy et al., 2011). 
The lipid antigens present in microorganisms (mycobacteria) or endogenous tissues, 
are presented to the lymphocytes by DCs through CD1 molecules. These are essential in 
presenting specific glycolipids to NKT cells. Plasmacytoid DC do not have CD1 molecules 
(Arosa, A. F., Cardoso, E.M., 2011; Goldsby, R.A., Kindt, T. J., Osborne, B., Kuby, J, 
2007). 
Moreover, the role of DCs in the activation of B cells is mainly indirect, through 
induction of expression of CD40L and IL-2 on T lymphocytes (important factors in the 
activation of B lymphocytes). 
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In conclusion, DCs are central in the initiation and regulation of adaptive immune 
responses which makes these cells a promising target in anti-tumor treatments (Benencia et 
al., 2012). 
 
1.4) Anti-tumor immunity  
Activating the immune system for therapeutic benefit in cancer has long been a goal 
in immunology and oncology. 
The generation of an effective anti-tumor immune response is a complex multistep 
process and the understanding of this matter provides a rationale for immunotherapeutic 
strategies (Buckanovich et al., 2008; Mellman, Coukos e Dranoff, 2011; Pardoll, 2012). 
Advances in the understanding of how tolerance, immunity and immunosuppression 
regulate anti-tumor immune responses suggest that active immunotherapy represents a 
means to obtain a durable and long-lasting response in cancer patients.  
For anti-tumor immunity to be effective three distinct steps must be achieved, either 
spontaneously or therapeutically: immunization, T cell response and blocking 






Figure 2 – Sites for therapeutic intervention that allow regulated anti-tumoral immunity. Increased 
presentation of tumor antigens by mature dendritic cells leads to more effective adaptive immune response 
mediated by T cells and help to prevent immunosuppression. Adapted from Mellman et al., (Mellman, 
Coukos e Dranoff, 2011). 
 
| 14   
 
The anti-tumor response must begin with the uptake of tumor-associated antigens, 
exogenously or captured from dead or dying tumor cells by immature dendritic cells.  
The dendritic cells process the captured antigen for presentation or cross-
presentation on MHC class II and class I molecules, respectively, and migrate to draining 
lymph nodes. However, during capture and presentation it is necessary an adequate 
stimulus (activation signal) to mature dendritic cells is present. This stimulus depends of 
the concentration of the antigen, and the intensity and duration of the interaction with 
lymphocytes. 
Activation signals could be therapeutically supplied in an exogenous (for example, 
TLR - ligands) or endogenous manner: dying or necrotic tumor cells release factors (for 
example, high mobility group proteins or ATP) that are thought to result in the 
immunogenic maturation of dendritic cells (Mellman, Coukos e Dranoff, 2011). Thus it 
initiated the antitumor response mediated by anti-cancer effector T cells.  
The T cells of the immune system must first be able to recognize cancer cells as 
foreign, to generate a population of CTLs that can traffic to and infiltrate tumors wherever 
they reside, and specifically bind to and kill cancer cells (Chen, Irving e Hodi, 2012). 
However, if there is no accompanying maturation, DCs can induce tolerance leading to the 
elimination of T cells, T cell anergy or differentiation of Treg cells (Chen, Irving e Hodi, 
2012).  
In addition to the activation of CD8+ and CD4+ T cells, dendritic cells may also 
trigger antibody and NK or NKT cells responses, which may contribute to the tumor 
immunity (Mellman, Coukos e Dranoff, 2011) 
Additionally, tumors may downregulate their expression of MHC class I molecules 
or their expression of target tumors antigens (Hamanishi et al., 2007; Kooi et al., 1996). 
The number of predicted MHC Class I-associated neoantigens was correlated with cytolytic 
activity and was lower than expected in colorectal and other tumors, suggesting immune-
mediated elimination (Rooney et al., 2015). 
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Therefore, the importance of the maturation state of DCs is essential and key to 
whether the type of anti-tumor response is adequate and effective. 
 
1.5) Immunotherapy  
The conventional treatment for cancer includes routinely surgical resection and a 
combination of chemotherapy and radiotherapy. These approaches are often accompanied 
by unintended collateral damage and highly toxic to healthy tissues, which are offset by 
only marginal improvements in prognosis in patients with advanced cancers. This 
unfortunate balance has driven the development of new therapies aimed at achieving tumor 
elimination both safely and efficiently. 
Over the last decade, increasing evidence supports a therapeutic utility of the 
immune system by immunotherapy. The aim of this strategy is to enable, restore, manage 
and still complement the patient's own immune system to control tumor growth and 
dissemination (Aris e Barrio, 2015). Sometimes pre-existing anti-tumor T cells can be 
ineffective in the elimination of the tumor for several reasons: due to their low frequency, 
the selection of tumor cells to escape recognition by the immune system, or even because 
these lymphocytes are functionally disabled (Aris e Barrio, 2015).  
Among other immunotherapy approaches, vaccines can be prophylactic and 
therapeutic (Palucka, Banchereau e Mellman, 2010). Prophylactic (or preventative) 
vaccines have been used with considerable success for the prevention of cancers of viral 
origin, such as hepatitis B virus and human papillomavirus (HPV), where the etiological 
agent is known. In contrast, the development of therapeutic vaccines to treat existing 
disease has proven problematic. The long history of failure has tainted the entire strategy of 
immunotherapy in the eyes of many oncologists. 
The idea of a therapeutic cancer vaccine began with the discovery that patients can 
harbour CD8+ and CD4+ T cells specific for cancer-testis or differentiation antigens 
expressed in their tumors (Boon et al., 2006). Vaccination might reasonably be expected to 
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amplify the frequency and strength of these pre-existing responses or perhaps induce some 
de novo reactions. Therapeutic vaccines can be administered as adjuvant therapy after 
excision of tumors, with the aim of overcoming immunosuppression produced by the tumor 
and its microenvironment, to stimulate specific immune effectors that can destroy tumor 
cells or to increase the immunogenicity of the tumor to induce long-lasting immunity. 
Additionally, clinic-pathological studies have demonstrated a strong association 
between prolonged patient survival and the presence of intra-tumoral CD8+ cytotoxic T 
cells and an IFN-γ gene signature (Galon et al., 2006; Zhang et al., 2003). Thus, if 
vaccination could trigger these types of T cell responses, a clinical benefit might be 
expected. 
In general, vaccines require two critical components, the source of Antigen and 
adjuvant (Batchu et al., 2005). Therapeutic vaccines include the use of different antigenic 
sources, such as, antigen peptides, proteins, nucleic acids, tumor cells lysates, recombinant 
virus or irradiated whole cells (Aris e Barrio, 2015).  
 
1.6) Vaccines based on DCs 
Alternatively, since the mid-90s, DCs have been used in clinical trials as cellular 
mediators for therapeutic vaccination of cancer patients (Anguille et al., 2014). The use of 
DCs in an immunotherapeutic strategy is based on its ability to initiate cellular immune 
responses through the stimulation of naive T cells. Immature DCs are good at antigen 
uptake and processing, but for a stimulatory T-cell response they must mature to become 
fully activated DCs, which express high levels of cell surface-related MHC antigen and 
costimulatory molecules. Because of their ability to stimulate T cells, DCs act as a link 
between innate immunity and adaptive immunity in anti-tumor immune responses 
(Banchereau e Steinman, 1998). 
DCs play a central role in various immunotherapy protocols aimed at the generation 
of CTLs (Reid, 2001). DC-based vaccines have become the most attractive tool for cancer 
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immunotherapy and have been used in the treatment of more than 20 malignancies, most 
commonly melanoma, renal cell carcinoma, prostate cancer, and colorectal carcinoma 
(Palucka, Ueno e Banchereau, 2011; Ridgway, 2003). Since tumor antigen-loaded DCs are 
expected to be able to stimulate tumor-specific CTLs and to overcome T cell tolerance in 
tumor patients, the development of DC vaccines that can consistently eliminate minimal 
residual neoplastic disease remains an important goal in the field of tumor immunology 
(Banchereau e Palucka, 2005).  
However, much skepticism has been shown due to the uncertainty of their clinical 
efficacy, since only some patients have an effective response. However, the clinical benefit 
of DC-based immunotherapy is small, but real, whereby 8.5% of patients with melanoma 
achieved an objective response. The DC therapy is as effective as dacarbazine, the standard 
of care chemotherapy, where 5-15% of patients show an objective response (Anguille et al., 
2014).  
In 2010, the FDA approved Sipuleucel-T, the first DC-based vaccine for the 
treatment of metastatic castrate resistant, hormone refractory prostate cancer (Beer et al., 
2011). 
 
1.6.1) DC vaccine optimization  
The key step in this approach lies in producing a DC vaccine capable of eliciting an 
immune response that is capable of destroying the tumor. The vaccines based on DCs are 
composed of DCs that are generated from peripheral blood precursors (i.e., monocytes, 
HSCs) or bone marrow progenitor cells and are educated ex vivo with tumor antigens prior 
to vaccination in patients (fig.3) (Lee et al., 2012; Steinman e Banchereau, 2007) .  









Despite this simplistic picture (fig.3), there are several strategies used to activate 
DCs and to obtain a more effective vaccine. The use of immature DCs or mature DCs, the 
way to induce DC maturation, the type of tumor antigen, the techniques used to load tumor 
antigens to DCs, routes of administration, and dosing schedules are all being investigated 
(Figdor et al., 2004).  
It has been demonstrated by several authors (Boog et al., 1989; Cabral et al., 2013; 
Crespo et al., 2009; Jenner et al., 2006) that changes in the glycosylation of the dendritic 
cell surface, more specifically sialylation, influences the subsequent activation of these 
cells and their role in induction of immune responses. 
 
1.7) Glycosylation  
Glycosylation is a post-translational modification more commune in proteins of 
eukaryotic cells has a frequency of 50% (Hang e Bertozzi, 2005; Wopereis et al., 2006). 
This process involves covalent attachment of one or more glycans consisting of 
Figure 3 - Key points to improve DC vaccination in cancer patients. Adpated from Lee et al., (Lee et al., 
2012). 
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monosaccharides to a protein, lipid, carbohydrate or any other organic component, forming 
a glycoconjugate (Reis et al., 2010; Varki et al., 2009). 
Glycoconjugates are involved in many physiological and pathological processes, 
including the processes of differentiation, cell migration and signaling, host-pathogen 
interactions and tumor invasion and metastasis (Campbell e Yarema, 2005; Reis et al., 
2010). 
Glycans classes which are found in eukaryotic cells are defined based on the nature 
of the glycan binding to the carrier molecule (protein or lipid), forming in this way, various 
glycoconjugates (fig.4). Thus, glycoconjugates can be classified into proteoglycans, 
glycosphingolipids, glycosylphosphatidylinositol bound proteins and glycoproteins (Li e 


















Glycoproteins are defined as glycoconjugates in which one or more oligosaccharide 
chains are covalently linked to a protein (Ohyama, 2008; Reis et al., 2010; Varki et al., 
2009). There are two types of glycans associated with glycoproteins based on the type of 
Figure 4 - Glycoconjugates classes expressed in human cells. Adapted from Reis et al., (Reis et al., 
2010). 
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attachment: N-glycans and O-glycans. Both types of glycosylation can exist simultaneously 
within the same molecule and in the same cell. An N-glycan is an oligosaccharide 
covalently bound to the nitrogen atom of asparagine residues within a type amino acid 
sequence Asn-X-Ser / Thr (X being any amino acid except proline). O-glycan is a 
oligosaccharide covalently bound to the oxygen atom of a serine or threonine residue in an 
amino acid sequence (Li e Richards, 2010; Taniguchi, N., et al., 2008; Varki et al., 2009). 
There are many ways in which the O-glycans may be elongated and processed with 
the addition of terminal residues to these structures, namely the addition of sialic acid, 
fucose and/or sulfate. These terminal residues often determine the biological function as 
well as recognition properties of modified glycans (Varki et al., 2009). 
 
1.7.2) Sialic acids 
Sialic acids (Sias) constitute a large family of terminal monosaccharides, which 
include N-acetylneuraminic acid (Neu5Ac) and derivatives thereof, which typically are 
attached to the expressed glycoconjugates on the cell surface of animal tissues and certain 
microorganisms (Varki e Schauer, 2009). Sias are involved in many cellular functions, both 
in physiological and pathological processes, including the regulation of the immune system, 
triggering infection and progression of certain diseases (Varki, A., Angata, T, 2006; Varki, 
A., et al. 2009) .  
Sias are unique sugars that usually occupy the terminal position of the glycan chains 
and may be modified by external factors, such as pathogens, or upon specific physiological 
cellular events (sialidases). At cell surface, sialic acid-modified structures form the 
fundamental key determinants for a number of receptors with known involvement in 
cellular adhesiveness and cell trafficking, such as the selectins and thesialic acid-binding 
Ig-like lectins (Siglecs). 
Siglecs are the best-characterized I-type lectins involved in the recognition of sialic 
acids (Angata, T., Brinkman-Van der Linden, 2002) and they are characterized by their 
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binding specificity for terminal sialic acids (Aarnoudse et al., 2006). Siglecs are expressed 
predominantly on cells of the immune system (Crocker, Paulson and Varki, 2007), such as 
human immature DCs and are in particular highly expressed on tolerogenic DCs. 
Siglecs are thought to play a role in both positive and negative regulation of 
immune responses (Crocker, Paulson e Varki, 2007; McMillan e Crocker, 2008) and cells 
that express high levels of siglecs, such as DCs, are crucial for initiation and differentiation 
of immune responses (Bax et al., 2011). 
 
1.7.3) Desialylation   
Interestingly, sialic acid-modified structures are involved in all DC functions, such 
as antigen uptake, DC migration, and capacity to prime T cell responses. Sialic acid content 
changes along DC differentiation and activation and these changes have important 
implications in DC function. 
Videira et al. (Videira et al., 2008) observed that the removal of sialylated structures 
through treatment with a sialidase diminishes the endocytic capacity of moDCs, suggesting 
a maturation trigger of these cells. Boog et al. (Boog et al., 1989) showed that removal of 
sialic acids in non-responder types of APC in mice restores specific failure of T cells to 
respond to nominal antigen or autoantigen, leading to the idea that sialylation contributes to 
dampening of immune functions. Crespo et al, (Crespo et al., 2009) indicated that sialidase 
treatment increases the expression of MHC and of co-stimulatory molecules and affects 
some functionality of DCs resulting in onset of maturation 
 
1.8) Hypothesis, Aims and Scopes  
 
As reported above sialic acid content affects dendritic cell function and a high sialic 
acid content is associated with lower efficiency of DC-based immune responses. However, 
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it is still unclear how sialic acid content affects DC activation and their capacity to prime T 
cells. 
In this thesis, the hypothesis is: the capacity of human dendritic cells to activate 
antigen specific T cells is most effective when cell surface sialic acids are removed from 
dendritic cells. We also hypothesized that TLR signaling is improved in desialylated DCs. 
The aims of this thesis were: 
o To characterize moDCs with altered sialic acid content,  by an extrinsic enzymatic 
treatment with sialidase, evaluating their maturation profile and cytokine 
expression; 
o To analyze the effect of sialic acid shortage in TLR-mediated signaling. To address 
this we used HEK-cell lines overexpressing Toll-like receptors. 
o To investigate effect of sialidase treatment on gp100 peptide (melanoma antigen) 
binding to MHC-I. For this T2 cells (TAP-deficient) were used. 
o To evaluate the ability of dendritic cells with altered sialic acid content to modulate 
T cell-specific responses.  
 To study CD8+ T-cells activation, we used primary human moDCs treated or 
untreated with sialidase that were co-cultured with CD8+ T-cell clones, with 
a specific TCR for the gp100 peptide, in the presence of two types of gp100 
peptide: a gp100 short peptide (YLEPGPVTA) and a gp100 long peptide 
(YLEPGPVTANRQLYPEWTEAQRLDC). The amino acid binding motif 
for HLA-A*is underlined. HLA-A*0201, an allele of MHC class I, is 
frequent in the Caucasian population (~50%). Therefore, these epitopes also 
have the potential to be recognized by gp100 specific CD8+ T cell clones. 
Peptides derived from the gp100 protein, a known melanoma antigen, were 
used since there are already several well characterized models available, 
including T cell clones with specific receptors for peptides derived from this 
antigen.  
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 To study CD4+ T cell proliferation, primary human moDCs treated or 
untreated with sialidase were co-cultured with different ratios of CD4+ T-
cells isolated from PBLs.  
With this work, we expect to elucidate whether desialylation of human DCs 
improves the DC capacity to activate T cells, with the potential to improve cytotoxic 
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Figure 6 - Layout of separation by ficoll gradient. 
2) Materials & Methods 
2.1) Human peripheral blood  
Human monocytes were isolated from buffy coats of healthy donors (Sanquin, 
Amsterdam, The Netherlands) through a Ficoll and subsequent Percoll gradient. Informed 
consent was given by all donors for the use of their blood samples. 
 
2.2) Isolation of monocytes from buffy coats by Ficol and Percol gradient 
Peripheral blood mononuclear cells (PBMCs) were isolated by sequential density 
gradient centrifugation. The first step in this process consists of diluting 50 ml of buffy coat 
in 130 ml of phosphate buffered saline solution (PBS; BRAUN) containing 1% citrate 
(PBS-Citrate). This solution was mixed very gently and added to a 50 ml tube containing 
10 ml of Ficoll. Afterwards the Ficoll gradient was centrifuged at 700 x g for 30 minutes, 
without brake.  
Ficoll is a hydrophilic polysaccharide with a particular density, superior to PBMCs, 
but inferior to erythrocytes and granulocytes, allowing a specific separation of the different 
components, after centrifugation. At this point, blood components are separated by density 
gradient and four phases are distinguishable: erythrocytes, present as pellet, followed by 
Ficoll, with the PBMCs at the interface 
and right beneath the most abundant 
layer, which corresponds to plasma and 
the majority of the platelets (fig.5). 
PBMCs were collected and transferred 
to 50 ml tubes. PBMCs were washed 
twice in 50 ml PBS-Citrate. The cell 
suspension was centrifuged first at 
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400 x g for 10 minutes, and subsequently at 300 x g, for 4 minutes. Afterwards cells were 
resuspended in 50 ml RPMI-1640 medium (Gibco, UK) supplemented with 10% Fetal Calf 
Serum (BioWhittaker) and counted using  trypan blue (1:10), in order to determine the total 
number of live PBMCs. Cell count was always performed using the Neubauer chamber 
(104). The total number of live PMBCs is determined as follows: 
Total no. live cells = cells counted (without coloration) × DF × 104 × solution final volume (ml) 
(1) 
Before starting with the Percoll isolation the cell were centrifuged once more at 300 
x g, for 4 minutes. 
The next process was aimed at separating the monocytes and lymphocytes using a 
Percoll gradient. For this isolation to be successful it is essential to perform the entire 
process at room temperature (22 °C) because the Percoll is very temperature-sensitive. 
PBMCs were resuspended in RPMI-1640 medium supplemented with 10% Fetal 
Calf Serum (22 °C) at a concentration of 10 million cells per ml. 50 ml tubes were prepared 
with 15 ml Percoll (Percoll ,1.5M NaCl, MQ water) each and 15 ml of PBMCs were added 
slowly and carefully on top of the Percoll layer. The Percoll gradient was subsequently 
centrifuged at 400 x g for 40 minutes, at 22 °C (acc=4, dec=1, added delay 10 minutes). 
The ring of cells, containing 70% to 96% monocytes depending on the starting amount in 
PBMC, was collected and transferred to new 50 ml tubes. Tubes were filled up to 50 ml 
with PBS-citrate, and centrifuged at 400 x g, for 10 minutes, at 22 °C with brake. The cells 
were washed at least three more times in 50 ml PBS-Citrate and centrifuged at 300 x g, for 
4 minutes. Finally, the cells were resuspended in 50 ml RPMI-1640 medium supplemented 
with 10% Fetal Calf Serum and counted using a trypan blue (1:10), as describe above in 
(1). The percentage of live “monocytes” from PBMCs is determined as follows:  
% of live monocytes from PBMCs =  
𝒕𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒎𝒐𝒏𝒐𝒄𝒚𝒕𝒆𝒔
𝒕𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝑷𝑩𝑴𝑪𝒔
 × 𝟏𝟎𝟎    (2) 
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2.3) Generation of monocyte-derived dendritic cells (moDCs) 
After Percoll isolation, the monocytes were resuspended in RPMI-1640 medium 
supplemented with 10% Fetal Calf Serum (FCS), Interleucine-4 (IL-4, 500 U/ml), and 
granulocyte macrophage colony-stimulating factor (GM-CSF, 800 U/ml) (both from 
BioSource/Invitrogen, Carlsbad, CA, USA). 15 million monocytes were seeded per T75 
flask in 12 ml medium. The cells were kept in culture at 37 ºC, in a humidified atmosphere 
with 5% CO2, to promote the differentiation into dendritic cells (DCs). After 4-5 days the 
monocytes have differentiated into dendritic cells (moDCs). 
 
2.4) Sialidase treatment 
MoDCs (0.5 million of cells) were incubated for 60 min at 37 °C with 25 mU/ml of 
sialidase (Roche, USA) in serum-free RPMI-1640 medium or DMEM medium (Gibco, 
UK) and subsequently, washed and resuspended in serum-free RPMI-1640 medium or 
DMEM medium. In parallel, a control lacking sialidase was incubated under the same 
conditions containing the same amount of cells.  
 
2.5) Lectin binding assay 
The binding of sialic acid-specific plant lectins (Table 1), Sambucus nigra 
agglutinin (SNA) and Maackia amurensis agglutinin I and II (MAA II and MAL-I, all from 
Vector Laboratories, Burlingame, CA) to moDCs with or without sialidase treatment 
(describe in 2.4 section) was determined by flow cytometry. The cells were incubated with 
the lectins at a final concentration of 5 µg/ml for 30 minutes at 37°C. Lectins were diluted 
in Hank’s buffered saline solution (HBSS, Gibco, UK) containing 0.5% of BSA (Roche, 
USA). After washing twice in the same medium the cells were incubated with Alexa 488-
labeled Avidine (Molecular probes, USA) for 30 min at 37 °C. After one final washing step 
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with HBSS/BSA, the samples were transferred to FACS tubes and analyzed in a 
FACSCalibur (BD Biosciences, San Diego, CA, USA). If the samples could not be 





2.6) MoDC stimulation 
After sialidase treatment of the moDCs, as describe in 2.4 section, treated and 
untreated moDCs were plated (1x105 cells/well) and incubated overnight, at 37 °C in the 
presence or absence of Toll-like Receptor (TLR) stimulation.  
The TLR ligands (Table 1) used were: Lipopolysaccharide (LPS (Escherichia coli) - 
TLR4-ligand, 10 ng/ml; Sigma-Aldrich), Triacylated lipopeptide (Pam3CysK4 - TLR2-
ligand, 5 μg/ml; Invivogen), or Resiquimod (R848 - TLR7/8-ligand, 5 μg/ml; Invivogen). 
TLR ligands were diluted in RPMI-1640 supplemented with 1000 U/ml 
penicillin/streptomycin (Lonza), 2 mM glutamine (Lonza) and 10% FCS (BioWhittaker) – 
RPMI-1640 complete medium. 
Table 2 – Lectin specificity. Representation of the structure, the lectin name, the 
organism origin and its binding specificity. Adapted from Varki, et al.,(Varki et al., 
2009). 
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After O/N incubation, moDCs were centrifuged at 300 x g for 2 minutes and 65 μl 
of supernatant was harvested and frozen at -80 °C for future evaluation of cytokine 
secretion by ELISA. Subsequently, cells were resuspended in 100 μl of PBA (PBS -Fisher 
Scientific, USA, with 0.5 % of BSA and Azide) and transferred to a V-bottom plate, 
whereby each original well was divided into two separate wells in the V-bottom plate. After 
washing at 300 x g for 3 minutes, cells were incubated for 30 minutes at 4 °C with 
phycoerythrin-conjugated antibodies to CD markers (BD Biosciences, diluted in PBA) for 
the analysis of DC maturation. The CD markers that we used were CD83, CD80 and CD86 
(all from BD Biosciences). After incubation, cells were washed with 100 µl PBA, 
centrifuged at 300 x g for 3 min and then resuspended in 100 µl of PBA and transferred to 
FACS tubes. Cells were analyzed on the FACS Calibur.  
 
2.7) Toll-Like Receptor (TLR) test  
The Human Embryonic Kidney (HEK) cells (kindly provided by Douglas 
Golenbock, University of Massachusetts Medical School, Worcester, USA) is a genetically 
modified cell line that expresses TLR-2 (HEK-TLR2), TLR-4 (HEK-TLR4), or TLR-8 
(HEK-TLR8). They can be used to determine TLR activation upon the stimulation with 
respective TLR ligand by assessing IL-8 production (only cytokine secreted by these type 
of cells).  These cell lines were grown in DMEM medium supplemented with 1000 U/ml 
penicillin/streptomycin, 10 % FBS and 0.5 mg/ml geneticin (G418). 2.5 million of cells 
were treated or left untreated, as described in 2.4 section.. After washing, cells were plated 
(1x105 cells/well in 100 μl of DMEM medium supplemented with 1000 U/ml 
penicillin/streptomycin and 10% FBS) in a 96 wells flat bottom plate and allowed to adhere 
for 90 min. Afterwards 50 µl of medium was removed and 50 µl of TLR ligand were added 
in different concentrations: LPS (Escherichia coli, TLR4-ligand, 100-1 ng/ml; Sigma-
Aldrich), Pam3CysK4 (TLR2-ligand, 5-0.5 μg/ml; Invitrogen) or R848 (TLR8-ligand, 50-
0.5 μg/ml; Invitrogen). Cells were incubated for 24 hours at 37 ºC in a humidified 
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atmosphere with 5% CO2. After incubation 50 µl of supernatant was harvested for IL-8 
analysis by sandwich ELISA. 
2.8) Enzyme-linked Immunosorbent Assay (ELISA) 
The cytokine levels in supernatants (IL-10, IL-12p70, IL-8, IL-6, tumor necrosis 
factor alpha (TNF-α), interferon-γ (INF-γ)) were determined by Sandwich ELISA using an 
antibody pairs from Life Technologies. The capture antibody was resuspended in coating 
buffer (50 mM Na2CO3, pH 9.7) (APPENDIX I) and added to the 96 well ELISA plate 
(100 µl/well) overnight (ON) at 4 ºC. After two washes with 200 µl/well ELISA washing 
buffer (PBS 1x containing 0.05% Tween20 (Sigma Aldrich)) wells were blocked with 200 
µl/well of blocking buffer (PBS 1x and 1% BSA) for 30 minutes at 37 ºC. After two more 
washes, 100 µl of samples were added, in duplicate, to each well. Depending on the type of 
cytokine measured, the sample dilution was adjusted (Table 4). Human cytokine Standards 
were diluted in blocking buffer (APPENDIX I) to make a standard curve. In addition, 50 µl 
of the detection antibody diluted in blocking buffer (APPENDIX I) was added to each well. 
Plates were sealed and incubated for 2 hours at room temperature (RT) under mild shaking. 
After washing 4 times with ELISA washing buffer, 100 µl/well of streptavidin-HPR 
(Invitrogen, 1:10.000 dilution in ELISA washing buffer) was added and incubated at RT for 
30 minutes. After extensive washing with ELISA washing buffer (6 times) 100 µl/well of 
substrate solution (100 µl of 10 mg/ml 3,3′,5,5′-tetramethylbenzidine (TMB), 1 µl 30% 
H2O2 in 10 ml of substrate buffer (0.1 M citric acid/0.1 M sodium acetate, pH 4.0)). The 
reaction was stopped by the addition of 50 μl of 0.8 M H2SO4. Plate were read at 450 nm 
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IL-8 TLR-2 : 1:10 
IL-8 TLR-4 : 1:2 





2.9) Real-Time PCR (qPCR) 
For determining the mRNA expression levels of interleukin (IL)-6, IL-10, IL-12p40 
and TNF-α) in moDCs a qPCR was used. MoDCs were treated prior with sialidase or left 
untreated (shown in 2.4 section) and after over-night incubation with TLR stimulation 
(shown in 2.6 section) cells were lysed and mRNA was isolated at indicated time-points 
using an mRNA Capture kit (Roche, Indianapolis, IN, USA). In short, lysates were 
incubated with biotin-labeled oligo(dT)20 for 5 min at 37°C and subsequently transferred to 
streptavidin-coated tubes and incubated for 5 min at 37°C.  
After washing twice, cDNA was synthesized using the Reverse Transcription 
System kit (Promega, Madison, WI, USA) following manufacturer’s guidelines. In brief, 30 
μl of the reverse transcription mix was added (5 mM MgCl2, 1× reverse transcription 
buffer, 1 mM of deoxyribonucleotides phosphated (dNTP), 0.4 U recombinant RNasin 
ribonuclease inhibitor, 0.4 U of avian myeloblastosis virus reverse transcriptase (AMV 
RT), 0.5 μg random hexamers in nuclease-free water) and incubated for 10 min at room 
temperature, 90 min at 42°C, and 5 min denaturing at 99°C. 
Then the amplification was performed with specific primers for each cytokine 
referred to above. Primers were designed using Primer Express 2.0 (Applied Biosystems, 
Carlsbad, CA, USA) and synthesized by Invitrogen. Glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH) was used as an endogenous reference gene (García-Vallejo et al., 
2004).  
The reaction mixture consisted of 4 μl Fast SYBR Green Master Mix (Applied 
Biosystems), 0.2 μl of the primer solution containing 5 nmol/μl of both primers, 1.8 μl 
H2O, and 2 μl of a 1:2.5 dilution of the cDNA solution. PCR reactions were run for 2 min at 
50°C, followed by 10 min at 95°C and 40 cycles of 15 s at 95°C and 1 min 60°C. PCR 
reactions were run on a ViiA 7 sequence detection system (Applied Biosystems). The Ct 
value is defined as the number of PCR cycles where the fluorescence signal exceeds the 
threshold value which is fixed at 10 times the standard deviation of the fluorescence during 
the first 15 cycles and typically corresponds to 0.2 relative fluorescence units (Vliet, Van et 
al., 2013). GAPDH served as an endogenous reference gene (García-Vallejo et al., 2004). 
 The Ct values normalized for target and GAPDH mRNA (Nt) is determined as 
follow: 
Nt = 2Ct(GAPDH) - Ct(target)      (3) 
 
2.10) DC loading   
Tumor antigen used for DC loading are usually a peptide derived from a tumor 
associated protein. In this assay, the tumor antigen is a peptide derived from the gp100 
protein, a known melanoma antigen. Peptides were synthesized and purity was determined 
as described previously (Hooijberg et al., 2000). The peptide was selected for binding to 
specific major histocompatibility complex (MHC) molecule, thus guarantying that it will be 
presented to peptide-specific T cells as described previously (Fehres et al., 2015; Skipper et 
al., 1999).  
Two types of gp100 peptide were used: a gp100 short peptide (YLEPGPVTA) and a 
long gp100 long peptide (YLEPGPVTANRQLYPEWTEAQRLDC). The amino acid 
sequence underlined binds to HLA-A*0201, an allele of MHC class I, that is frequent in the 
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Caucasian population. The gp100 long peptide is internalized through phagocytosis and 
during processing the peptide is cleaved and the resultant short peptide (underlined) 
becomes available to form a peptide–MHC-I complex and to be presented through MHC 
class I to CD8+ cytotoxic T cells, a phenomenon known as antigen cross-presentation. In 
this way, these epitopes have the potential to be recognized by gp100 specific CD8+ T cell 
clones.  
 
2.11) Peptide binding assay  
For this assay a T2 - TAP (Transporter Associated with Antigen Processing) 
deficient cell line was used.  
TAP-competent cells translocate endogenously generated peptides into the 
endoplasmic reticulum (ER) where they are loaded onto MHC class I molecules. These 
peptides are derived from cellular proteins degraded in the proteasomal complex (Kisselev 
et al., 1999). TAP-deficient cells lack the transporter for MHC class I-restricted peptides to 
enter the ER endoplasmatic reticulum. The absence of ER-localized peptides in TAP-
deficient cells results in the accumulation of empty MHC class I molecules in the ER-Golgi 
intermediate compartments as well as on the cell surface. These empty MHC molecules can 
be rapidly loaded by available peptides (Raposo et al., 1995). Therefore, exogenous 
peptides can potentially be loaded onto MHC complexes at the cell surface directly.  
First of all the T2 cells were cultured till confluency and then harvested 
(4×106cells/mL). The cells were divided and washed. Half of the cells (2×106cells/mL) 
were incubated with sialidase and the other half (2×106cells/mL) was incubated without 
sialidase as described in section 2.4. After washing the cells were resuspended in serum-
free RPMI-1640 medium with 6 µg/ml of β2-microglobulin (Sigma-Aldrich, St. Louis, MO) 
and plated 100.000 cells/well (50 µl/well).Then, gp100280–288 (short) peptide 
(YLEPGPVTA) was used in three different concentrations: 100 µM, 10 µM and 1 µM. 
After 4 hours of incubation at 37 °C the cells were transferred to a V-bottom plate and 
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thereafter the T2 cells were washed with PBA (PBS with 0.5% of BSA and Azide) and 
stained with PE-labelled anti-HLA-A2+ antibody (clone BB7.2, PharMigen) for 30 min, at 
4 °C. Lastly, the cells were washed with PBA and transferred to tubes to be analysed. 
Peptide-mediated stabilization of HLA-A2+ molecules at the cell surface of T2 cells was 
detected by flow cytometry. Figure 2 is a schematic representation of T2 binding assay.  
For each assay, lectin binding assay was performed in parallel to verify the 







2.12) Activation of CD8+ T cell clones 
MoDCs were treated with sialidase (5 × 106 moDCs) or left untreated (5 × 106 
moDCs) as described in section 2.4, and then were washed. After this, LPS (100 ng/ml; 25 
μl/well) was added or not to half of the treated cells and half of the untreated cells and then 
the cells were plated (30,000 cells/well; 25 μL/well). The peptides were added (50 μL/well) 
in different concentrations: gp100 long peptide (30 μM, 10 μM, 3 μM, and 1 μM); gp100 
short peptide at 10 μM. The short peptide is used as a positive control, because it can 
immediately be loaded onto MHC-I molecules displayed at moDCs cell surface and thus 
easily be presented to T cells, without being requiring further processing.  
Figure 7 - Summary of the MHC-I binding assay with T2 cells. Prior to the assay T2 cells were treated 
with sialidase or left untreated. After a wash step T2 cells were resuspended in serum-free RPMI-1640 
medium with β2-microglobulin and plated in the presence of gp100280–288 (short) peptide. After 4 hours of 
incubation at 37 °C the cells were stained with PE-labelled anti-HLA-A2+ antibody. 
| 35   
 
After 3 h of incubation at 37 °C the moDCs were washed twice with serum-free 
RPMI-1640 medium, before they were co-cultured with the CD8+ T cells. The CD8+ T cells 
was originated from a CD8+ T clone with a TCR specific for the gp100 peptide (as 
described in 2.10 section) were thawed and washed two times with 25 ml of in RPMI-1640 
complete medium, then resuspended in IMDM medium (Gibco, UK) and added 100.000 
cells/well (100 μl/well) to 96-well-plate. T cells (100.000 cells/well) with (10 ng/ml) of 
phorbol myristate acetate (PMA) and 500 ng/ml of ionomycin (Io) (both from Sigma) are 
used as a positive control for the assay (graph not shown). 
After overnight or 3 days of incubation at 37 °C, supernatants were harvested and 
IFN-γ levels were measured by sandwich ELISA using specific antibody pairs from 
Biosource as described in section 2.8. 
 
2.13) CD4+ T cell Proliferation 
MoDCs were treated with sialidase (5×106 moDCs) or left untreated (5×106 moDCs) 
as described in section 2.4, and then washed. After this, LPS was added or not, as described 
in previous section and the cells were incubated for 3 h at 37 °C.  
CD4+ T cells were prepared as follows: Peripheral blood lymphocytes (PBLs) HLA-
A2+ (obtained by Ficol/Percol isolation from peripheral blood) were thawed and then 
washed three times with serum-free RPMI medium. Autologous CD4+ T cells were isolated 
using a MACS CD4+ T cell negative isolation kit (Miltenyi Biotec), according to the 
manufacturer’s rules. In short, PBLs were washed with 25 ml of buffer (PBS + 2mM of 
EDTA + 1% FCS) and after centrifugion, 400 μl of MACS buffer and 100 μl Ab-cocktail (a 
cocktail of biotin-conjugated antibodies against CD8a, CD11b, CD11c, CD19, CD45R 
(B220), CD49b (DX5), CD105, Anti-MHC-class II, Ter-119 and TCRγ/δ as primary 
labeling reagent) were added to PBLs (100 x 106 cells) and incubated 10 min at 4ºC. Then 
200 μL of beads were added to PBLs and incubated for 15 min at 4ºC. After this, the cells 
were washed with 25 ml of MACS buffer and the isolation was done. Finally CD4+ T cells 
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were washed, resuspended in IMDM medium and distributed in wells (100.000 cells/well) 
in a volume of 50 µl.  
After the incubation with LPS, the moDCs were washed with serum-free RPMI-
1640 medium and added at different ratios: 1:5; 1:10; 1:25; 1:50; 1:100 to CD4+ T cells. In 
order to detect proliferation of the CD4+ T cells, after 3 days of co-culture [3H]-thymidine 
incorporation into DNA (1 μCi/well; Amersham Biosciences, NJ, USA) was measured. 
After 24 h, cells were harvested onto filters and [3H]-thymidine incorporation was assessed 
using a beta scintillation counter. 
 
2.14) Statistical analysis  
Results were analyzed using a Student’s t-test using GraphPad Prism 6 software 
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3) Results 
This work had as a primary goal to evaluate how the desialylation of DCs affected 
their functionality, in particular their capacity to present antigen and activate T cells. To 
address this question, we first had to establish a method to desialylate DCs, based on the 
extrinsic treatment of DCs with a bacterial sialidase.  
 
3.1) Sialidase protocol optimization  
In order to analyze the effects of sialidase treatment on moDCs, the sialidase 
protocol was optimized first. To evaluate this, lectin binding studies with SNA (α2-6-linked 
sialic acids), MAA II (α2-3-linked sialic acids on O-glycan) and MAL I (α2-3-linked sialic 
acids on N-glycan) were done, to confirm that immature moDC express high levels of α-
2,3- and α-2,6-sialic acids (Videira et al., 2008). Different concentration of sialidase (20 
mU/ml and 40 mU/ml) and different incubation times (1h and 2h) were tested (fig.7). 
At both concentrations tested, sialidase can cleave α2-3-linked sialic acids on O- 
and N-glycans from the moDCs surface more efficiently than α-2.6 sialic acids, as shown 
by the large decrease in MAA II and MAL I binding. SNA binding does not seem to be 
affected by this treatment. (fig.7, a1)). However, there are no significant differences 
between the two concentrations used (20 mU and 40 mU). 
In the graph of % of positive cells, we can see that sialidase treatment can only 
affect the percentage of positive cells that bind to MAA II and this decrease is even bigger 
when 40mU/ml of enzyme was used, however 20 mU/ml also shows a visible decrease 
(fig.7, a2)). 
Incubation times of 60 min and 120 min are both effective, since at both time points 
a decrease in binding to all lectins can be observed (fig.7, b1)). In this graph (fig.7, b1)) 
SNA binding was reduced by the treatment with 20 mU/ml of sialidase, not observed in 
fig.7, a1, but the results derived from different donors witch can be influence. 
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Again treatment only affected the % of MAA II positive cells (fig.7, b2)), which 















Given these results, we decided to proceed with a standard treatment protocol using 
25 mU/ml of sialidase for 60 min at 37°C. The final concentration of sialidase chosen was 






















































Figure 12 - Lectin binding to cell surface of moDCs. MoDCs were stained with Sambucus nigra lectin (SNA 
- recognizing α2,6-sialic-acids) and Maackia amurensis lectin (MAA II - recognizing α2,3-sialic-acids on O-
glycans and MAL I - recognizing α2,3-sialic-acids on N-glycans) following sialidase treatment. 
a) Immature mo-DCs were treated with sialidase at two different concentrations (20 mU/ml and 40 mU/ml) or 
left untreated, for 60 min at 37 °C (n=1). Control results are represented in white, 20 mU of sialidase in black 
and 40 mU in grey: a1) Mean fluorescence intensity (MFI); a2) the percentage of positive cells. b) Immature 
mo-DCs were treated with 20 mU/ml of sialidase at two different incubation times (60 min and 120 min) or 
left untreated for 60 min at 37 °C (n=1). Controls results are represented in white, 60 min of incubation in 
black and 120 min of incubation in grey: b1) Mean fluorescence intensity (MFI)  ; b2) the percentage of 
positive cells. The results were obtained by flow cytometry, the results displayed in a) and b) are derived from 
different donors. 
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3.2) Removal of sialic acid from the moDC surface by sialidase treatment increased 
co-stimulatory molecule expression when stimulated with TLR-ligands 
 Previous studies (Cabral et al., 2013; Crespo et al., 2009; Videira et al., 2008) have 
shown that altering the surface desialylation on moDCs by sialidase treatment has several 
functional consequences. The triggering of maturation in moDCs by sialidase treatment can 
be an explanation for this observation, because maturation causes structural and functional 
alterations in moDCs. 
To assess the maturation status of the moDCs after sialidase treatment, we analyzed, 
by flow cytometry, the expression of maturation markers CD80, CD83 and CD86. Effects 
of Sialidase treatment were evaluated with or without stimulation with TLR-ligands. TLR-
ligands are generally used as inducers of maturation, as can be observed by the increased 
expression of co-stimulatory molecules in TLR-stimulated cells (fig.8) 
 However, an upregulation in co-stimulatory molecules expression can be seen in 
sialidase treated moDCs, especially in moDCs stimulated with R848 (TLR7/8 ligand), 
where a significant increase in all maturation markers was observed (fig.8). After 
stimulation with LPS, a significant increase in CD80 and CD86 markers was also observed 
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 To evaluate the efficiency of the sialidase treatment to remove sialic acids on 
moDCs surface, a lectin binding assay was carried out in parallel. As mentioned previously, 
during monocyte differentiation into moDCs, an increase in sialylated structures, 
specifically, α-2,3 and α-2,6 sialic acids is observed, showing the highest expression at  day 
4 (Videira et al., 2008). 
 In this assay the moDCs after the 4th day of differentiation were labeled with SNA 
(α2-6-linked sialic acid), MAA II (α2-3-linked sialic acid on O-glycans) and MAL I (α2-3-
Figure 13 - Expression of maturation markers, CD80, CD83 and CD86, in moDCs after stimulation with 
Pam3, LPS and R848 (TLR-2, TLR-4 and TLR-7/8 ligands, respectively). moDCs were treated with sialidase  
(60 min at 37 °C) or left untreated. After overnight incubation with TLR-ligands, moDCs were stained with 
antibodies to different CD markers. Co-stimulatory molecule expression was evaluated by flow cytometry. 
The results are the average mean fluorescence intensity (MFI) of 15 independent assays. Statistical 
significance (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001) refers to the difference between untreated (white bar) and 
sialidase-treated moDCs (black-bar).  
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linked sialic acid on N -glycans) after sialidase treatment and the MFI was measured by 
flow cytometry. (fig.9).  
 Adramatic decrease in MFI of MAA II and MAL I to moDCs treated with sialidase 
can be observed. The % of positive cells for MAA II binding MAA II decreased to 
approximately 40% after sialidase treatment. 
 
3.3) Cytokine secretion is not affected in moDCs treated with sialidase  
To complement the results obtained by flow cytometry, where the sialidase treatment 
increased the expression of co-stimulatory molecules, suggesting the induction of 
maturation in moDCs, we analysed the secretion of several cytokines, IL-10, IL-12p70, IL-
6 and TNF-α by ELISA, after over-night stimulation with different TLR-ligands (fig.10). 
Our results suggest that sialidase treatment does not significantly affect the production 
of cytokines by moDCs in any of the conditions tested. However, it is possible to see a 
tendency for an increase of cytokine secretion by treated-moDCs in the presence of LPS 
and a tendency for the decrease of cytokine secretion by -moDCs in the presence of the 
R848 stimulus, especially for IL-10, IL-6 and TNF-α (fig.10). 
Figure 14 - Plant lectin binding assay. moDCs (day4 after of differentiation) were treated with sialidase  (60 
min at 37 °C) or left untreated and then were labelled with the different plant lectins (SNA, MAA II and MAL 
I). lectin binding was evaluated by flow cytometry. The results are the average mean fluorescence intensity 
(MFI) (left side) or percentage of positive cells (right side) of 16 independent assays. Statistical significance 
(**p ≤ 0.01; ***p ≤ 0.001) refers to the difference between untreated (white bar) and sialidase-treated moDCs 
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Previous studies (Cabral et al., 2013; Crespo et al., 2009) , where cytokine levels 
wereanalyzed by qPCR-real time, did show an increase in expression in treated-moDCs 
compared to untreated moDCs.  
As the results of the present study didn’t support the literature, we decided to analyze 
cytokine production of one donor, by ELISA and qPCR-real time, in order to compare the 
results obtained by both techniques (cytokines secretion and transcript levels of cytokines, 
respectively). All cytokines studied before (IL-6, IL-10, IL-12p70 and TNF-α) in treated 
and untreated moDCs were assessed by ELISA. IL-6 and TNF-α were measured after 6h of 
incubation after ON incubation. As IL-10 and IL-12p70 could probably not be detected 
after 6 h, they were only measured after ON incubation. All incubations were done in the 
presence of TLR-ligands (fig.11). 
Figure 15 - Cytokine secretion. MoDCs were treated with sialidase (black bar) for 60 min at 37 °C or left 
untreated (white bar). After over-night incubation with different TLR-ligands the supernatant was harvested 
and cytokine production was measured by ELISA. The results are the mean ± SEM of 9 independent 
experiments.  
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Figure 16 - Cytokine production analysed by ELISA (left side) and qPCR (right side). moDCs were treated 
with sialidase (60 min at 37 °C) or left untreated. After incubation for 6 h (grey bar and blue bar) or over-
night (white bar and black bar) with different TLR-ligands, the supernatant was harvested and the cytokine 
production was measured by ELISA. Cell pellets were lysed and cytokines mRNA levels were measured by 
qPCR. The results are of 1 independent experiment. 
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With the exception of IL-12p70 that was not detectable by ELISA, for the other 
cytokines it was possible to compare results obtained by both techniques. The secretion of 
IL-10, IL-6 and IL-12p70 seem to be decreased in cells that have previously suffered the 
sialidase treatment, while TNF-α secretion was found to increase in the presence of R848 
stimulus. Overnight incubation led to higher cytokine concentrations compared to only 6 h 
incubation (fig.11) 
Thus, our results still do not match the literature, but we can see that for the same 
donor, transcript levels of cytokines and the extracellular secretion followed the same 
pattern, which leads us to conclude that the analysis by ELISA is reliable.  .  
 
3.4) Sialidase treatment and TLRs activation 
In order to elucidate the mechanism of action of sialidase we proceeded to test whether 
we could observe a direct effect of sialidase treatment on TLR activation. To test this, HEK 
cell lines stably expressing specific TLR receptors were used (HEK-TLR-2, TLR-4 and 
TLR-8),.  
The treatment with sialidase in HEK cell lines was done according to the treatment 
used for moDCs, as described in section 2.4. each cell line (HEK-TLR-2, TLR-4 and TLR-
8) was subsequently incubated ON at 37 °C with the respective stimulus (Pam3, LPS, or 
R848). After incubation, supernatant was harvested to measure the IL-8 cytokine secretion 
by ELISA (fig.12). 
As shown in fig 12, sialidase treatment does not affect IL-8 production in either the 
TLR-4 nor TLR-8 receptors (fig.12). On the other hand, TLR-2 activation appears to be 
affected by sialidase treatment, since there was a little decrease in IL-8 production, 
although not significant, in treated cells, when the Pam3-ligand was used as a stimulus 
(fig.12) 













3.5) Desialylation effect in gp100 short peptide binding to HLA-A2 in T2 cell line 
To understand whether treatment with sialidase had any effect on the binding of 
gp100 peptide to MHC-I, a binding assay with a T2 cell line was carried out. 
This cell line is TAP deficient, implying that only when peptide binds to MHC-I, it 
remains on the cell surface, whereas otherwise the MHC-I is endocytosed and recycled. For 
this test, cells were treated for 1h at 37 °C with sialidase or left untreated, and then washed. 
The cells were subsequently incubated 3/4h or ON with different concentrations of gp100 
short peptide (1 µM, 10 µM and 100 µM) in the presence of β-microglobulin to help the 
stabilization of the peptide-MHC I-complex. Thereafter, cells were stained with a specific 
Figure 17 - Toll like receptor test. HEK cells were treated with sialidase for 60 min at 37 °C or left untreated. 
After incubation over-night with different TLR-ligands the supernatant was harvested and the IL-8 production 
was measured by ELISA. TLR-2 results are the mean ± SEM of 4 independent experiments, TLR-4 results 
are of one representation experiment out of 3 and the TLR-8 results are the mean ± SEM of 3 independent 
experiments. Statistical significance (*p ≤ 0.05) refers to the difference between untreated (black line) and 
sialidase-treated (blue line) HEK cells. 
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Figure 18 – gp100 peptide bound MHC-I is more stable on sialidase treated T2 cells. a) T2 binding assays 
were performed by incubating clls, treated (blue line) or not (black bar) with sialidase, without peptide (ss 
why not just call this zero?) or with different concentrations of gp100 short peptide in the presence of β-
microglobulin for 4h at 37 °C. After incubation, T2 cells were washed and stained with anti- HLA-A*02 
antibody, for 30 min at 4 ºC and analyzed by flow cytometry. Results were normalized to the condition 
without peptide and without sialidase treatment. Graph show the mean ±SEM of at least 4 independent 
experiments. b) As a control T2 cells were treated (black bar) with sialidase or left untreated (white bar) and 
the cells were labeled with different plant-lectins (SNA, MAA II and MAL I) to ensure the effectiveness of 
sialidase treatment. Graph shows the mean ±SEM of at least 4 independent experiments and statistical 
significance (*p ≤ 0.05) refers to the difference between untreated and sialidase-treated T2 cells. 
antibody to anti-HLA-A2 and analyzed by flow cytometry (fig.9, a)). In parallel, the cells 
were also labelled with lectins (SNA, MAA II and MAL I) to check the efficiency of 
sialidase treatment (fig.9, b)). 
The lectin binding results demonstrate that sialidase treatment was effective, as 
shown by the more than 50% decrease in lectin binding to the surface of the T2 cells (fig.9, 
b)). 
The peptide binding results are not significant, but we can still observe a little 
increase in the levels of MHC-I in treated cells when they are incubated with peptide but 
also without peptide (fig.9, a)). Treated and untreated cells have a very parallel stabilization 
curve. Moreover, T2 cells treated with sialidase but without peptide have also higher levels 
of MHC-I which may indicate that, besides the stabilization effect, it seems that MHC-I is 
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3.6) Sialidase treatment of moDCs improves their ability to activate tumor antigen 
gp100-specific T cells 
DCs have a unique ability to present exogenous antigens via MHC-I molecules, a 
function designated as cross-presentation. Exogenous antigens (gp100 long, in this case) 
are degraded by proteasomes and coupled to MHC-I molecules for presentation to naïve 
CD8+ T lymphocytes (CTL). This process ensures that DCs can create a cytotoxic immune 
response against tumor or infected cells. The CTL are characterized by the production of 
IFN- γ and TNF- α cytokines. 
To assess if the activation of gp100 tumor antigen -specific CD8+ T cell clones was 
enhanced by moDCs treated with sialidase the IFN- γ production by these T-cells was 
measured, in a presence of two types of peptide, gp100 short and gp100 long peptide 
(described in 2.10 section). 
The gp100 long peptide is internalized through phagocytosis and during processing 
the peptide is cleaved and the resultant short peptide (underlined in 2.10 section) becomes 
available to form a peptide–MHC-I complex and to be presented through MHC class I to 
CD8+ cytotoxic T cells, a phenomenon known as antigen cross-presentation. In this 
manner, the epitopes have the potential to be recognized by gp100 specific CD8+ T cell 
clones. 
The usual treatment of moDCs with sialidase was done, as describe in section 2.4, 
LPS was added (fig.14, b) and d)) or not (fig.14, a) and c)) to treated or untreated cells and 
then the cells were plated. The peptides were added in different concentrations: gp100 long 
peptide: 30 μM, 10 μM, 3 μM, 1 μM; gp100 short peptide: 10 μM.  After 3 h of incubation 
at 37 °C cells were washed and the CD8+ T cell clones specific for gp-100 peptide were 
added. After ON (fig.14, a) and b)) or 3 day (fig.14, c) and d)) incubation at 37 °C, 
supernatants were harvested and IFN-γ levels were measured by sandwich ELISA. Results 
were normalized to the IFN-γ levels obtained with the incubation with short peptide 
without sialidase treatment. 
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As shown in fig.14, a), sialidase treatment of moDCs without without LPS 
stimulation appears to increase their ability to activate CD8+ T cell clone after overnight 
incubation. This observation is more prominent in the presence of gp100 long peptide at 
concentrations between 30-10 µM. With lower peptide concentrations, sialidase treatment 
did not alter the activation of T cells. Furthermore, the activation of T cells co-cultured with 
moDCs treated with sialidase is also increased in the presence of gp100 short peptide. That 
is, both the direct presentation and the cross-presentation appear to be more effective in 
moDCs treated with sialidase.  
However, when CD8+ T cells were kept in culture with moDCs for 3 days (fig.10, c) 
and d)), the difference in activation of T cells by moDCs treated and untreated appears to 
be greater when moDCs are stimulated with LPS specially in the presence of 30-3 µM of 
gp100 long peptide and gp100 short -peptide. 
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3.7) Sialidase treatment of moDCs improves proliferation of autologous CD4+ T cells 
The proliferation of autologous CD4+ T cells was assessed by [3H]-thymidine assay. 
The usual treatment with sialidase was done to moDCs, as describe in section 2.4LPS was 
added or not (Fig.9, a) and b) respectively) to treated or untreated cells for 3 h at 37 °C. 
Autologous CD4+ T cells were isolated and co-cultured with moDCs in different ratios: 1:5; 
Figure 19 - Improved production of IFNy by CD8+ T cell clones. a) gp100-specific CD8+ T cells were co-
cultured overnight with gp100-loaded moDCs, that have previously been treated (black bar) or not (white bar). 
b) gp100-specific CD8+ T cellswere co-cultured overnight with gp100-loaded moDCs and LPS, after 
treatment (black bar) or not (white bar) with sialidase. c) gp100-specific CD8+ T cellswere co-cultured for 3 
days with gp100-loaded moDCs after treatment (black bar) or not (white bar) with sialidase. d) gp100-specific 
CD8+ T cells were co-cultured for 3 days with gp100-loaded moDCs and LPS after treatment (black bar) or 
not (white bar) with sialidase. Different concentrations of long gp100 peptide, which is cross-presented to  
CD8+ T cells, were used. The short gp100 peptide was used as a positive control for the functionality and 
antigen specificity of  CD8+ T cell clone. The secretion of the IFN-γ cytokine was measured by ELISA (n=3).  
Results were normalized to the IFN-γ levels after incubation with short peptide without sialidase treatment (a) 
and c)) or with short peptide without sialidase treatment and with LPS (b) and d)). 
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1:10; 1:25; 1:50; 1:100. After 3 days (at 37°C) [3H]-thymidine was added for 24 h to detect 
incorporation into the DNA of proliferating CD4+ T cells.  
Figure 9 shows that compared to untreated moDCs the moDCs treated with 
sialidase, irrespective of their LPS stimulation, seem to increasee CD4+ T cell proliferation. 
T cells display a maximal proliferation at the ratio is 1:25 when co-cultured with immature 
moDCs (Fig.9, a)). At a ratio of 1:50 there is a significant increase in the proliferation of T 
cells co-cultured with treated moDCs (Fig.9, a)). The proliferation of T cells in the 
presence of mature moDCs is maximal at a ratio of 1:10 (Fig.9, b)). At a ratio of 1:100 a 
significant increase is observed in the proliferation of T-cells co-cultured with moDCs 
treated with sialidase (Fig.9, b)).  
To obtain significant results it will be necessary to repeat the assay to increase the 
sample size. 
Figure 20 - Sialidase treatment of moDCs improves proliferation of autologous CD4+ T cells. The 
proliferation of purified CD4+ T cells was measured by [3H]thymidine uptake assay, after a challenge with 
different ratios of moDCs that were treated (black bar) or not treated (white bar) with sialidase, in the absence 
a) or in the presence b) of LPS for 3 days (n=3). Results were normalized to the condition without moDCs 
and without sialidase treatment (a) or without moDCs, without sialidase treatment and with LPS (b). Graphs 
show the mean ± SEM of at least 3 independent experiments. 
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4) Discussion and conclusions 
With the progression of the glycobiology field, sialic acids have revealed an 
important role in the modulation of immune responses and are therefore a therapeutic target 
of great interest. However, our knowledge is still not as thorough to the point where we can 
understand all the mechanisms involved in its action. 
It has been reported by many authors that the α2-6 and α2-3 sialylated structures on 
the surface of some immune cells are modulated according to cell differentiation and 
maturation (Marino et al., 2004; Moody et al., 2003). 
Dendritic cells in particular, are antigen presenting cells bearing a large endocytic 
capacity (Cabral et al., 2013). It has been demonstrated by several researchers that human 
monocyte-derived dendritic cells (moDCs) are highly sialylated (Sallusto et al., 1995; 
Videira et al., 2008). These sialylated structures modulate the operation of moDCs, for 
instance their endocytosis capacity, degree of activation and maturation (Crespo et al., 
2009; Silva, Konstantopoulos e Videira, 2012), which are all key features in the regulation 
of immune response mediated by lymphocytes. Due to its potent immunoregulatory 
capacity, dendritic cells are very promising therapeutic targets in the use for vaccines for 
cancer therapy.  
It is now well accepted that the content of sialic acid on the cell surface can be 
modulated by endogenous sialidases such as Neu1 (Kooyk, van et al., 2004) as well as by 
sialidases from exogenous sources, for instance, released by pathogens in the course of an 
infection (Cabral et al., 2013). 
This thesis is aimed at evaluating the structural/functional consequences of 
elimination of sialic acids on the moDCs surface through the action of an exogenous 
sialidase, a hydrolase which cleaves the glycosidic bonds of neuraminic acids (α2-3, α2-6 
and α2-8). 
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First we show that treatment with sialidase and subsequent addition of Toll like 
receptors (TLR) agonists induces dendritic cell maturation, thereby increasing the amount 
of some costimulatory molecules on the surface of these cells especially when stimulated 
with R848 (fig.8). However, in the absence of any stimulus, sialidase treatment alone does 
not interfere with the maturation moDCs (fig.8), suggesting that the maturation effect is the 
result of both triggers simultaneously. Amith et al. (Amith et al., 2010), describe that in 
primary BM macrophage cells, the removal of α-2,3-linked sialyl residues by Neu1 
sialidase is essential for TLR dimerization and subsequent cellular signaling to activate 
NFκB. It is possible that the action of the sialidase results in increased responsiveness of 
the moDCs to the TLR agonists (LPS, PAM3, R848). As described by Amith et al. (Amith 
et al., 2010) TLR4 receptors have less α-2,3-sialylated structures after activation by LPS 
when compared to the non-activated TLR4.  
Furthermore, during the desialylation has cross intermediary molecules signaling 
between the cell surface and TLRs as immunoregulatory Siglecs (Crocker, Paulson e Varki, 
2007; O’Neill, 2008). Human moDCs express several receptors, such as Siglecs, that 
recognize sialic-acid-containing glycans, that may have preferences for either the Sia(α2,3) 
linked to Gal(β1,3)GalNAc or the Sia(α2,6) to Gal(β1,4)GalNAc (Varki e Angata, 2006). 
Siglecs have the potential to interact not only in trans with sialylated ligands found in other 
cells, but also in cis with ligands found at the surface of the same cell (Varki e Angata, 
2006).  
When Siglecs bind to sialic acid containing glycans, they trigger an intracellular 
inhibitory signal which prevents the signaling of membrane TLRs as no production of 
inflammatory cytokines is found (Stamatos et al., 2010). However, in the presence of 
sialidase, these sialic acids are removed and there is a reduction in binding to Siglecs, 
abrogating the inhibitory signaling therefore downstream events in the signaling pathway of 
TLR continue, culminating in inflammatory cytokine production (Paulson e Kawasaki, 
2011). 
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When moDCs were treated with the sialidase enzyme and stimulated with the 
TLR7/8 ligand R848, a significant increase was observed in all co-stimulatory molecules 
studied, CD80, CD84 and CD86 (fig.8). As the TLR7 and 8 receptors are intracellular, it 
will be necessary to perform sialidase internalization studies to identify the signaling 
pathway responsible for this increase. 
While the enzyme treatment has led to extensive desialylation, as measured by 
significant reduction in the binding of lectins MAA II and MAL I to moDCs (fig.9), there 
were no significant differences in the detected amount of cytokines in the medium of 
treated cells with sialidase and in the medium of untreated cells (fig.9). This was not 
expected since the moDCs showed signs of maturation (fig.8), which could result in the 
production of inflammatory cytokines.  
It is possible that desialylation of glycoconjugates is important for intracellular 
cytokine production and the amount of sialidase was not sufficient to activate the 
production of these effectively. Another reason relates to the possibility that the sialidase 
action is reversed by regeneration of sialic acids to the cell surface by means of 
sialyltransferase activity present in or on the DCs, as described by Stamatos et al. 
(Stamatos et al., 2010), and therefore does not modulate the most delayed mechanism 
involved in cytokine production. 
Earlier, our laboratory already verified (Cabral et al., 2013) that an increase in 
cytokine production in moDCs treated with sialidase. However, the enhancement in 
cytokine production by moDCs treated with sialidase occurred only in some of the donors 
(fig.10) whereas in other donors cytokine production in treated moDCs production was 
lower than in untreated moDCs or even sometimes no differences were found. These results 
have not been reproducible, and all together, show no significant differences in cytokine 
production from sialidase treated and untreated moDCs.  
Thus, it was necessary to quantify the production of cytokines by ELISA 
(evaluating the overall amount of cytokines produced by moDCs into the medium), and by 
Real Time-PCR simultaneously, (assessing the amount of mRNA corresponding to each 
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intracellular cytokine). Besides Real Time-PCR is a more sensitive technique that was also 
used by Cabral et al. (Cabral et al., 2013). In our study the amount of cytokines showed a 
slight increase in moDCs treated with sialidase as measured by both techniques (fig.11). 
However, the results still did not show significant differences so it would be necessary to 
increase the sample size to draw conclusions.  
By comparing the present results with the previous results by Cabral et al. (Cabral et 
al., 2013) it is also necessary to take into account the difference in the method used for the 
isolation of monocytes. The isolation method used here was a Ficoll/Percol gradient, 
whereas Cabral et al. (Cabral et al., 2013) was used isolation by positive selection of 
CD14+ monocytes (MACS). As several authors describe (Elkord et al., 2005; Normann et 
al., 2010; Zhou et al., 2012) the isolation method of monocytes can influence the activation 
state of the dendritic cells and this could modulate the cytokine production.  
In order to elucidate the mechanisms of sialidase treatment on TLR triggering, 
sialidase assays were carried out in HEK-TLR transfectants. The results of these 
experiments suggest that sialidase treatment did not affect TLR triggering as no significant 
differences were found in the production of the IL-8 cytokine (fig.12). This result was 
unexpected since in dendritic cells the desialylation seems to involve in TLR mechanism 
(fig.8), but this activation may be a consequence of the action of the sialidase on Siglecs as 
described above. This leds us to consider that the two different cell types (moDCs versus 
HEK-TLR transfectants) might respond differently to desialylation, thus providing  a 
possible reason for these results, although it is interesting to study the mechanism with 
other cellular models.  
Crespo et al. (Crespo et al., 2009) showed that MHC expression increases in 
sialidase treated moDCs, and therefore we analyzed whether desialylation directly affects 
the stability of MHC-I in a T2 binding assay. MHC class I antigen presentation and cell 
surface expression depends primarily on peptide transport into the ER/Golgi by the 
transporter for antigen presentation (TAP) (Lankat-Buttgereit e Tampe, 2002). 
| 55   
 
T2 cells are deficient in TAP but still express low amounts of MHC class I on the 
cell surface  (No Title, [s.d.]). The T2 binding assay is based upon the ability of gp100 short 
peptide (YLEPGPVTA) to stabilize the MHC class I complex on the surface of the T2 
cells. Although no significant differences were observed between treated and untreated 
cells (fig.13, a)), a slight increase in the direct binding of gp100 short peptide, especially in 
the presence of concentrations of peptide 10-100 µM, to MHC-I cells treated with the 
enzyme was observed. However, even in sialidase treated cells that were incubated without 
peptide (fig.13, a)) a slight increase in the expression MHC-I could be seen,which leads us 
to consider that, regardless of the presence of peptide, the treatment with the enzyme alone 
can affect this complex and therefore its basal expression. This is even supported by 
extensive desialylation as shown by a significant decrease in lectins binding (SNA, MAA II 
and MAL I) to treated T2 cells (fig.13, b)). 
Together, these results show that the action of sialidase might directly interfere with 
peptide binding to MHC-I, and subsequently the presentation to T cells, but to conclude 
this, it would be necessary to repeat the test to a reasonable sample size. 
In addition to the direct presentation of peptide to MHC-I, the ability of DCs to 
cross-present tumor antigens has long been a focus of interest to scientists that aim to 
establish efficient cell-based cancer immune therapy. cross-presentation allows exogenous 
antigens to access the processing and presentation machinery of a cell so that exogenous 
antigenic peptides are displayed on MHC class I molecules for T cell recognition, which 
consequently leads to the priming of CD8+ T cell responses (Fehres et al., 2014). As such, 
the cross-presentation pathway is essential for inducing cytotoxic T-lymphocyte (CTL) 
responses against tumor antigens (Platzer, Stout e Fiebiger, 2014). Indeed, cross-priming of 
tumor reactive cytotoxic CD8+ T cells through cell-based tumor vaccines is a major goal in 
cancer immunotherapy (Andersen e Ohlfest, 2012; Apetoh et al., 2011). Hence, it is 
important to better understand the mechanisms that underlie the induction of tumor-specific 
cytotoxic T-lymphocyte (CTL) responses initiated by DCs via cross-presentation. 
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to mimic this process in vitro,  the capacity of sialidase treated and not treated 
moDCs , in the presence (Fig. 14, b) and d)) or absence (Fig.14, a) and c)) of LPS, to 
activate CD8+ T cell clones was assessed. We used  different concentrations of two gp100 
peptides, the gp100 short peptide that is presented directly to MHC I and consequently can 
used as a positive control and the gp100 long peptide that needs to be cleaved 
intracellularly to be cross-presented via MHC I.  
A CD8+ T cells was used that contains a TCR that specifically recognizes part of 
amino acid sequence of the gp100 protein (YLEPGPVTA). MoDCs were cultured 
overnight (fig.14, a) and b)) or 3 days (fig.14, c) and d)) with CD8+ T cell clone and the 
amount of IFN-γ released by T-cells was measured by ELISA. 
The results of the fig.8 show that, the amount of gp100 peptide, sialidase treatment, 
stimulation with LPS and the culture time are all factors that appear to determine the 
activation of the cytotoxic T cells. In the absence of LPS the activation of the CD8+ T cell 
clone appears to be upregulated when they are cultured overnight with sialidase treated 
moDCs, in the presence of both gp100 short peptide and gp100 long peptide at 
concentrations of 30-10 µM (Fig. 14, a)). Thus, both the direct presentation as well as the 
cross-presentation of the long gp100 peptide seems to be improved under these conditions, 
since the production of IFN-γ increases, so the effect on sialidase may affect both 
pathways. When cytotoxic T cells were incubated with moDCs without LPS after 3 days 
their activation (fig.14, b)) in general is smaller, as there was no difference when using 
sialidase treated moDCs or untreated moDCs. So to compare the consequence of sialidase 
effect on the moDC-mediated activation of CD8+ T cells it is better to co-culture both cells 
ON.  
However, the opposite happens when T cells are incubated with mature moDCs. In 
treated and LPS-stimulated moDCs overnight incubation with the  CD8+ T cell clone did 
not increase the activation of these T cells both in the presence of gp100 short and gp100 
long peptides (fig.14 b)), but if the incubation is continued for at least 3 days, the activation 
of T cells appears to increase under these conditions (fig.14, d)), which leads us to consider 
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that the activation of CD8+ T cells by treated moDCs in the presence of LPS requires at 
least 3 day of incubation before the highest activation of these T cells can be noted.  
It would be very important to increase the number of assays in these tests, since 
these were not enough to get statistically significant results, but it is noticeable that the 
sialidase treatment has a tendency to enhance the activation of CD8+ T cells. 
To further investigate the functional effect of sialidase treatment on moDCs, we also 
evaluated the ability of either sialidase-treated or untreated moDC to induce proliferation of 
autologous CD4+ T cells. A defining aspect of the adaptive immune system is its capacity 
to elicit antigen-specific cellular immune responses by the instruction of antigen-specific 
CD4+ and CD8+ T cells. This property is entirely based on the presentation of antigen in 
MHC molecules (the peptide–MHC complex) and its recognition by the T cell receptor. 
The loading of extracellular antigen in MHC-II, recognized by CD4+ T cells, occurs in a 
different intracellular compartment than the loading of antigen in MHC-I, recognized by 
CD8+ T cells (Fehres et al., 2014). 
Autologous CD4+ T cells were isolated from peripheral blood using a MACS CD4+ 
T cell negative isolation kit and co-cultured with sialidase-treated or untreated moDCs, 
with or without LPS stimulus, in different ratios: 1:5; 1:10; 1:25; 1:50; 1:100. After 3 days, 
proliferation of the CD4+ T cells was assessed by [3H]-thymidine incorporation.  
According to our results, the number of proliferating CD4+ T lymphocytes is 
significantly increased when moDCs without LPS stimulation lose their surface sialic acids 
(fig.15, a), especially in a ratio of 1:50.  
This study did not evaluate the expression of MHC in sialidase-treated moDCs, 
however, our laboratory has previously demonstrated that sialidase-treated human DCs 
have increased expression of major histocompatibility complex (MHC) and costimulatory 
molecules, increased gene expression of specific cytokines and induce a higher proliferative 
response of T lymphocytes (Crespo et al., 2009). Together, these data suggest that 
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clearance of cell surface sialic acids contributes to the development of a T helper type 1 
pro-inflammatory response. 
In conclusion, an increased sialidase activity in DCs may be capable of enhancing 
the immunogenicity of antigens and that removal of sialic acid unmasks the hidden 
epitopes. 
Sialidase treatment in DCs would have several advantages over the currently used 
DCs maturation protocols. Sialidase treatment together with TLR stimuli (LPS, PAM3, 
R848, for example) increase the maturation status as evidenced by the increased expression 
of costimulatory molecules on the moDCs surface. Moreover, these results demonstrate that 
sialidase treatment in moDCs seems to promote proliferation of helper T cells via 
presentation in MHC class II but also activation of cytotoxic T cells via direct presentation 
and cross-presentation of antigenic gp100 peptides in MHC class I. This means that both 
CD4+ and CD8+ tumor-specific T cells could be induced in patients by vaccines based on 
DCs with altered sialylation.  
The action of sialidases is not clear yet, but in the model with TAP-deficient T2 
cells the MHC I seem to be affected by the sialidase treatment. As such, it would be 
important to continue these studies to obtain a better understanding of the relationship 
between sialidase and MHC I. 
The model with the HEK-cells did not confirm a direct action of sialidase in 
activation of the TLR, but it would be good to test other model systems, seen that one of 
the results of sialidase treatment may indirectly affect these receptors. In future trials we 
should replicate the test with other cell types, that are structurally similar (in terms of 
surface receptors) to moDCs, since HEK-cells are a simplistic model in this term. 
Further functional studies are still required to understand the competence and 
immune modulatory capacities of desialylated DCs. Nevertheless, because surface 
sialylation influences the immunogenicity of DCs upon antigen loading, the findings of this 
thesis should have a particular relevance to DC-based therapies and they propose that 
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sialylation is an issue to be considered when refining the immunological parameters of 
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7) Appendixes  
 












IL-1ß Biosource AHC0612 1.0 mg/ml 1 µg/ml 1/1000 
IL-4 Biosource AHC0642 1.0 mg/ml 1 µg/ml 1/1000 
IL-6 Biosource AHC0562 1.0 mg/ml 0.5 µg/ml 1/2000 
IL-8 Biosource AHC0982 1.0 mg/ml 0.5 µg/ml 1/2000 
IL-10 eBioscience 14-7108-85 0.5 mg/ml 
0.25 
µg/ml 1/2000 
IL-12p40 Biosource AHC8122 1.0 mg/ml 1 µg/ml 1/1000 
IL-12p70 eBioscience 14-7128-82 0.5 mg/ml 0.5 µg/ml 1/1000 
TNFα Biosource AHC3712 1.0 mg/ml 1 µg/ml 1/1000 
IL-17A eBioscience 14-7178-85 0.5 mg/ml 0.5 µg/ml  1/1000 
IFNγ Biosource AHC4432 1.0 mg/ml 1 µg/ml 1/1000 
 
 





stock Detection Dilution 
IL-1ß Biosource AHC0519 0.5 mg/ml 0.75 µg/ml 1/700 
IL-4 Biosource AHC0749 0.5 mg/ml 0.4 µg/ml 1/1250 
IL-6 Biosource AHC0469 0.5 mg/ml 0.2 µg/ml 1/2500 
IL-8 Biosource AHC0789 0.5 mg/ml 0.2 µg/ml 1/2500 
IL-10 eBioscience 13-7109-85 0.5 mg/ml 0.25 µg/ml 1/2000 
IL-12p40 Biosource AHC7129 0.5 mg/ml 0.2 µg/ml 1/2500 
IL-
12(p40/p70) eBioscience 13-7129-81 0.5 mg/ml 0.5 µg/ml 1/1000 
TNFα Biosource AHC3419 0.5 mg/ml 0.5 µg/ml 1/1000 
IL-17A eBioscience 13-7179-85 0.5 mg/ml 0.5 µg/ml  1/1000 
IFNγ Biosource AHC4539 0.5 mg/ml 0.5 µg/ml 1/1000 
 
 
 BSA    - Bovine Serum Albumine Fraction V, Roche  
 1075094001, stored at 4oC 
 PBS 10x - Fisher Bioreagents BP399-1 
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 Assay Diluent (or Blocking buffer) - Dissolve 0.5 gram of BSA in 100 ml of PBS 1x.  
 Cytokine standards - stock of 10 ng/ml rec cytokine is stored at -20oC, this is 
generated from a lyophilized stock (stored at 4oC). Dilute 
powder by adding assay diluent to a concentration of 10 ng/ml. 
Incubate 15 minutes RT and aliquot 125µl/epje.  
NB IL-10 standard is stored at -80oC, freezer 2: 2.G.2 For IL-
12p70 ELISA, use IL-12p40 standard. 
 Streptavidin-HRP - Biosource, SNN2004, aliquoted and stored at -20oC.  
 Working aliqoute is stored at 4oC. 
 Coating buffer - 50mM Na2CO3 buffer pH 9.7.  
Dissolve 2.65 g of Na2CO3 (Merck 6398.5000) in 490 ml of 
Milli-Q. Adjust to pH 9.7 and fill up to 500 ml. Buffer is stored 
at 4oC 
 25% Tween20 solution - Dissolve 10ml of Tween20 (Sigma P5927) in 30ml PBS 
 ELISA wash buffer - Add 2ml of 25% Tween20 and 100ml of PBS 10x to 898 ml of 
Milli-Q 
 Blocking buffer - Dissolve 1 gram of BSA in 100 ml of PBS 1x. 
 DMSO - Fluka, 41647 
 10mg/ml TMB - Dissolve 50mg of TMB (Sigma T2885) in 5 ml of DMSO 
 Substrate-buffer - Dissolve 21.02 g of citric acid (Merck 244, C6H8O7·H2O) and 
8.2 g of sodium acetate (J.T Baker, 0258, CH3COONa) in 990 ml 
of Milli-Q and adjust to pH 4.0 with acetic acid (Riedel de Haen, 
33209). Fill up to 1 liter   
 Substrate solution - Add 100 μl of 10 mg/ml TMB and 1 µl 30% H2O2 in 10 ml  
substrate-buffer. Use immediately. 
 Stop Solution - 0.8 M H2SO4: Add 21 ml pure H2SO4 (Sigma 32,050-1) to 479 
ml of Milli-Q 
 Maxisorp 96 well ELISA plate - NUNC 442404 




1. Coat NUNC maxisorp 96 well ELISA plate with 100µl/well coating antibody 
(concentration and dilutions: see above) in coating buffer 
2. Seal the plate and incubate overnight at 4oC. 
3. Discard wells and wash two times with 200µl/well ELISA wash buffer. 
4. Block wells with 200µl/well of blocking buffer. 
5. Incubate the plate 30 minutes at 37oC 
6. Discard wells and wash 2x with 200µl/well (ELISA wash buffer) 
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IL-10 standard:  
 
1:  conc= 2000 pg/ml 5 ul stock  + 495 ul PBS/BSA 
2: conc =   800 pg/ml 200 l from 1 + 300 l PBS/BSA 
3: conc =   320 pg/ml 200 l from 2 + 300 l PBS/BSA 
4: conc =   128 pg/ml 200 l from 3 + 300 l PBS/BSA 
5: conc =     52 pg/ml 200 l from 4 + 300 l PBS/BSA 
6: conc =     20 pg/ml 200 l from 5 + 300 l PBS/BSA 
7: conc =       8 pg/ml 200 l from 6 + 300 l PBS/BSA 
8: blank         300 l PBS/BSA 
 
Standard all other cytokine dilutions: (stock-solution, 10 ng/ml) 
 
1: conc = 2000 pg/ml 100 l stock + 400 l PBS/BSA 
2: conc =   800 pg/ml 200 l from 1 + 300 l PBS/BSA 
3: conc =   320 pg/ml 200 l from 2 + 300 l PBS/BSA 
4: conc =   128 pg/ml 200 l from 3 + 300 l PBS/BSA 
5: conc =     52 pg/ml 200 l from 4 + 300 l PBS/BSA 
6: conc =     20 pg/ml 200 l from 5 + 300 l PBS/BSA 
7: conc =       8 pg/ml 200 l from 6 + 300 l PBS/BSA 
8: blank         300 l PBS/BSA 
 
8. After pipetting standards/samples, add 50µl/well of detection antibody 
(concentration and dilution: see above) in assay diluent 
9. Seal plate and incubate at RT for 2 hours, shaking 100 rpm. 
10. Discard wells and wash 4 times with 200µl/well ELISA wash buffer. 
11. Add 100µl/well of 1:10.000 diluted streptavidin-HRP in ELISA wash buffer 
12. Seal plate and incubate at RT for 30 minutes 
13. Discard wells and wash 6 times with 200µl/well ELISA wash buffer. 
14. Add 100µl/well of substrate solution to each well 
15. Incubate plate at RT for approximately 15 minutes (maximal 30 minutes!) 
16. Add 50µl of stop solution to each well 
17. Using ELISA reader, read plate at 450nm and analyse data by software microplate 
manager 5.2.1 
18. Settings in analysis for standard curve report: 
Regression type:  Cubic 
Transformation:  Log (conc)-linear (abs) 
Axis Transformation:  Log(x)-linear(x) 
 
 
